search
Back to results

Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure (ATMOSPHERE)

Primary Purpose

Chronic Heart Failure

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Enalapril
Aliskiren
Sponsored by
Novartis Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Heart Failure focused on measuring Chronic Heart Failure, Cardiovascular death, CHF hospitalization, morbi-mortality trial, outcome study, endpoint driven, plasma renin activity, renin angiotensin aldosterone system, direct renin inhibitors, BNP, KCCQ, eGFR, (NYHA class II to IV) with elevated, BNP and reduced LVEF

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria

Patients eligible for inclusion in this study had to fulfill all of the following criteria:

  1. Patients ≥ 18 years of age, male or female.
  2. Patients with a diagnosis of chronic heart failure (NYHA

    Class II - IV):

    1. LVEF ≤ 35% at Visit 1 (local measurement, within the past 6 months assessed by echocardiography, multiple uptake gated acquisition scan (MUGA), computerized tomography(CT) scan, magnetic resonance imaging (MRI) or ventricular angiography)
    2. Elevated BNP or NT-proBNP at Visit 1:

    BNP ≥ 150 pg/mL (or BNP ≥ 100 pg/mL and unplanned hospitalization for HF within the last 12 months prior to Visit 1) (according to local measurement). OR NT-proBNP ≥ 600 pg/mL (or NT-proBNP ≥ 400 pg/mL and unplanned hospitalization for HF within the last 12 months prior to Visit 1) (according to local measurement).

  3. Patients had to be treated with an ACEI at a stable dose enalapril 10 mg daily at least or any other ACEI, e.g. ramipril, quinapril, lisinopril, fosinopril, perindopril, trandolapril; based on equivalent doses, for at least 4 weeks prior to Visit 1
  4. Patients had to be treated with a beta-blocker, unless contraindicated or not tolerated, at a stable dose for at least 4 weeks prior to visit 1 (for patients not on target dose, according to local guidelines, or in absence of that medication, the reason should be documented).
  5. Written informed consent to participate in the study and ability to comply with all requirements.

Exclusion Criteria

Patients with any of the following were to be excluded from participation in the study:

  1. History of hypersensitivity to any of the study drugs including history or allergy to ACEIs as well as known or suspected contraindications to the study drugs or previous history of intolerance to high doses of ACEIs during up- titration process.
  2. Patients treated concomitantly with both an ARB and an aldosterone antagonist in addition to study drug at Visit 1.
  3. Current acute decompensated HF (defined as an acute exacerbation of a chronic heart failure status manifested by typical signs and symptoms of HF like dyspnea, fatigue etc., that may require IV therapy with diuretics, vasodilators and/or inotropic drugs).
  4. Symptomatic hypotension and/or less than 95 mmHg systolic blood pressure (SBP) at Visit 1 and/or less than 90 mmHg SBP at Visit 4.
  5. Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or major vascular surgery, percutaneous coronary intervention (PCI) or carotid angioplasty, within the past 3 months prior to Visit 1.
  6. Coronary or carotid artery disease likely to require surgical or percutaneous intervention within the 6 months after Visit 1.
  7. Right heart failure due to severe pulmonary disease.
  8. Patients with Diabetes Mellitus.

Sites / Locations

  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Active Comparator

Arm Label

Combination Aliskiren / Enalapril

Aliskiren

Enalapril

Arm Description

Aliskiren / Enalapril combination therapy-150 mg/10 mg titrated to 300 mg/ 10 mg film-coated tablets and administered orally.

Aliskiren monotherapy - 150 mg titrated to 300 mg film-coated tablets and administered orally.

Enalapril monotherapy -10 mg film-coated tablet and administered orally.

Outcomes

Primary Outcome Measures

Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization
Number of participants that had first occurrence of the composite endpoint, which is defined as either CV death or HF hospitalization due to HF.

Secondary Outcome Measures

Change From Baseline to Month 12 for the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score
Change from baseline to Month 12 for the Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score. KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. KCCQ clinical summary score is a composite assessment of physical limitations and total symptom scores. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.
All Cause Death
Number of patients - All-cause death. All-cause death is common in Heart Failure HF patients this measures how many patients had this event.

Full Information

First Posted
February 26, 2009
Last Updated
October 3, 2016
Sponsor
Novartis Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT00853658
Brief Title
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure
Acronym
ATMOSPHERE
Official Title
A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of Both Aliskiren Monotherapy and Aliskiren/Enalapril Combination Therapy Compared to Enalapril Monotherapy, on Morbidity and Mortality in Patients With Chronic Heart Failure (NYHA Class II - IV). The Study is Also Known as Aliskiren Trial of Minimizing OutcomeS in Patients With HEart Failure (ATMOSPHERE).
Study Type
Interventional

2. Study Status

Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
March 2009 (undefined)
Primary Completion Date
October 2015 (Actual)
Study Completion Date
October 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis Pharmaceuticals

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The study will evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy as compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Heart Failure
Keywords
Chronic Heart Failure, Cardiovascular death, CHF hospitalization, morbi-mortality trial, outcome study, endpoint driven, plasma renin activity, renin angiotensin aldosterone system, direct renin inhibitors, BNP, KCCQ, eGFR, (NYHA class II to IV) with elevated, BNP and reduced LVEF

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
7064 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Combination Aliskiren / Enalapril
Arm Type
Experimental
Arm Description
Aliskiren / Enalapril combination therapy-150 mg/10 mg titrated to 300 mg/ 10 mg film-coated tablets and administered orally.
Arm Title
Aliskiren
Arm Type
Experimental
Arm Description
Aliskiren monotherapy - 150 mg titrated to 300 mg film-coated tablets and administered orally.
Arm Title
Enalapril
Arm Type
Active Comparator
Arm Description
Enalapril monotherapy -10 mg film-coated tablet and administered orally.
Intervention Type
Drug
Intervention Name(s)
Enalapril
Intervention Description
Enalapril 10 mg film-coated tablet and administered orally.
Intervention Type
Drug
Intervention Name(s)
Aliskiren
Other Intervention Name(s)
SPP100
Intervention Description
Aliskiren 150 mg titrated to 300 mg film-coated tablet and administered orally.
Primary Outcome Measure Information:
Title
Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization
Description
Number of participants that had first occurrence of the composite endpoint, which is defined as either CV death or HF hospitalization due to HF.
Time Frame
up to End of Study (78 months)
Secondary Outcome Measure Information:
Title
Change From Baseline to Month 12 for the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score
Description
Change from baseline to Month 12 for the Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score. KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. KCCQ clinical summary score is a composite assessment of physical limitations and total symptom scores. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.
Time Frame
Baseline, Month 12
Title
All Cause Death
Description
Number of patients - All-cause death. All-cause death is common in Heart Failure HF patients this measures how many patients had this event.
Time Frame
up to end of study (78 months)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Patients eligible for inclusion in this study had to fulfill all of the following criteria: Patients ≥ 18 years of age, male or female. Patients with a diagnosis of chronic heart failure (NYHA Class II - IV): LVEF ≤ 35% at Visit 1 (local measurement, within the past 6 months assessed by echocardiography, multiple uptake gated acquisition scan (MUGA), computerized tomography(CT) scan, magnetic resonance imaging (MRI) or ventricular angiography) Elevated BNP or NT-proBNP at Visit 1: BNP ≥ 150 pg/mL (or BNP ≥ 100 pg/mL and unplanned hospitalization for HF within the last 12 months prior to Visit 1) (according to local measurement). OR NT-proBNP ≥ 600 pg/mL (or NT-proBNP ≥ 400 pg/mL and unplanned hospitalization for HF within the last 12 months prior to Visit 1) (according to local measurement). Patients had to be treated with an ACEI at a stable dose enalapril 10 mg daily at least or any other ACEI, e.g. ramipril, quinapril, lisinopril, fosinopril, perindopril, trandolapril; based on equivalent doses, for at least 4 weeks prior to Visit 1 Patients had to be treated with a beta-blocker, unless contraindicated or not tolerated, at a stable dose for at least 4 weeks prior to visit 1 (for patients not on target dose, according to local guidelines, or in absence of that medication, the reason should be documented). Written informed consent to participate in the study and ability to comply with all requirements. Exclusion Criteria Patients with any of the following were to be excluded from participation in the study: History of hypersensitivity to any of the study drugs including history or allergy to ACEIs as well as known or suspected contraindications to the study drugs or previous history of intolerance to high doses of ACEIs during up- titration process. Patients treated concomitantly with both an ARB and an aldosterone antagonist in addition to study drug at Visit 1. Current acute decompensated HF (defined as an acute exacerbation of a chronic heart failure status manifested by typical signs and symptoms of HF like dyspnea, fatigue etc., that may require IV therapy with diuretics, vasodilators and/or inotropic drugs). Symptomatic hypotension and/or less than 95 mmHg systolic blood pressure (SBP) at Visit 1 and/or less than 90 mmHg SBP at Visit 4. Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or major vascular surgery, percutaneous coronary intervention (PCI) or carotid angioplasty, within the past 3 months prior to Visit 1. Coronary or carotid artery disease likely to require surgical or percutaneous intervention within the 6 months after Visit 1. Right heart failure due to severe pulmonary disease. Patients with Diabetes Mellitus.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Novartis Investigative Site
City
Huntsville
State/Province
Alabama
ZIP/Postal Code
35801
Country
United States
Facility Name
Novartis Investigative Site
City
Mobile
State/Province
Alabama
ZIP/Postal Code
36608
Country
United States
Facility Name
Novartis Investigative Site
City
Mobile
State/Province
Alabama
ZIP/Postal Code
36693
Country
United States
Facility Name
Novartis Investigative Site
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85723-0001
Country
United States
Facility Name
Novartis Investigative Site
City
Hot Springs
State/Province
Arkansas
ZIP/Postal Code
71913
Country
United States
Facility Name
Novartis Investigative Site
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72204
Country
United States
Facility Name
Novartis Investigative Site
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72205
Country
United States
Facility Name
Novartis Investigative Site
City
Pine Bluff
State/Province
Arkansas
ZIP/Postal Code
71603
Country
United States
Facility Name
Novartis Investigative Site
City
Searcy
State/Province
Arkansas
ZIP/Postal Code
72143
Country
United States
Facility Name
Novartis Investigative Site
City
Beverly Hills
State/Province
California
ZIP/Postal Code
90211
Country
United States
Facility Name
Novartis Investigative Site
City
French Camp
State/Province
California
ZIP/Postal Code
95231
Country
United States
Facility Name
Novartis Investigative Site
City
Inglewood
State/Province
California
ZIP/Postal Code
90301
Country
United States
Facility Name
Novartis Investigative Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90073
Country
United States
Facility Name
Novartis Investigative Site
City
Modesto
State/Province
California
ZIP/Postal Code
95355
Country
United States
Facility Name
Novartis Investigative Site
City
Northridge
State/Province
California
ZIP/Postal Code
91325
Country
United States
Facility Name
Novartis Investigative Site
City
Sacramento
State/Province
California
ZIP/Postal Code
95825
Country
United States
Facility Name
Novartis Investigative Site
City
San Diego
State/Province
California
ZIP/Postal Code
92123
Country
United States
Facility Name
Novartis Investigative Site
City
Santa Monica
State/Province
California
ZIP/Postal Code
90404
Country
United States
Facility Name
Novartis Investigative Site
City
Westlake Village
State/Province
California
ZIP/Postal Code
91361
Country
United States
Facility Name
Novartis Investigative Site
City
Denver
State/Province
Colorado
ZIP/Postal Code
80218
Country
United States
Facility Name
Novartis Investigative Site
City
Littleton
State/Province
Colorado
ZIP/Postal Code
80120
Country
United States
Facility Name
Novartis Investigative Site
City
Boynton Beach
State/Province
Florida
ZIP/Postal Code
33437
Country
United States
Facility Name
Novartis Investigative Site
City
Daytona Beach
State/Province
Florida
ZIP/Postal Code
32117
Country
United States
Facility Name
Novartis Investigative Site
City
Fort Lauderdale
State/Province
Florida
ZIP/Postal Code
33316
Country
United States
Facility Name
Novartis Investigative Site
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33021
Country
United States
Facility Name
Novartis Investigative Site
City
Jacksonville Beach
State/Province
Florida
ZIP/Postal Code
32050
Country
United States
Facility Name
Novartis Investigative Site
City
Miami Lakes
State/Province
Florida
ZIP/Postal Code
33014
Country
United States
Facility Name
Novartis Investigative Site
City
Orlando
State/Province
Florida
ZIP/Postal Code
32803
Country
United States
Facility Name
Novartis Investigative Site
City
Wellington
State/Province
Florida
ZIP/Postal Code
33449
Country
United States
Facility Name
Novartis Investigative Site
City
Athens
State/Province
Georgia
ZIP/Postal Code
30606
Country
United States
Facility Name
Novartis Investigative Site
City
Augusta
State/Province
Georgia
ZIP/Postal Code
30904
Country
United States
Facility Name
Novartis Investigative Site
City
Gillespie
State/Province
Illinois
ZIP/Postal Code
62033
Country
United States
Facility Name
Novartis Investigative Site
City
Topeka
State/Province
Kansas
ZIP/Postal Code
66606
Country
United States
Facility Name
Novartis Investigative Site
City
Metairie
State/Province
Louisiana
ZIP/Postal Code
70006
Country
United States
Facility Name
Novartis Investigative Site
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70121
Country
United States
Facility Name
Novartis Investigative Site
City
Slidell
State/Province
Louisiana
ZIP/Postal Code
70458
Country
United States
Facility Name
Novartis Investigative Site
City
Auburn
State/Province
Maine
ZIP/Postal Code
04210
Country
United States
Facility Name
Novartis Investigative Site
City
Southfield
State/Province
Michigan
ZIP/Postal Code
48075
Country
United States
Facility Name
Novartis Investigative Site
City
St. Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Novartis Investigative Site
City
Lincoln
State/Province
Nebraska
ZIP/Postal Code
68506
Country
United States
Facility Name
Novartis Investigative Site
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68198
Country
United States
Facility Name
Novartis Investigative Site
City
Elmer
State/Province
New Jersey
ZIP/Postal Code
08318
Country
United States
Facility Name
Novartis Investigative Site
City
Laurelton
State/Province
New York
ZIP/Postal Code
11422
Country
United States
Facility Name
Novartis Investigative Site
City
Stony Brook
State/Province
New York
ZIP/Postal Code
11794
Country
United States
Facility Name
Novartis Investigative Site
City
Wiliamsville
State/Province
New York
ZIP/Postal Code
14221
Country
United States
Facility Name
Novartis Investigative Site
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
Novartis Investigative Site
City
Marion
State/Province
Ohio
ZIP/Postal Code
43302
Country
United States
Facility Name
Novartis Investigative Site
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29403
Country
United States
Facility Name
Novartis Investigative Site
City
Varnville
State/Province
South Carolina
ZIP/Postal Code
29944
Country
United States
Facility Name
Novartis Investigative Site
City
Germantown
State/Province
Tennessee
ZIP/Postal Code
38138
Country
United States
Facility Name
Novartis Investigative Site
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38120
Country
United States
Facility Name
Novartis Investigative Site
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37205
Country
United States
Facility Name
Novartis Investigative Site
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37212
Country
United States
Facility Name
Novartis Investigative Site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75226
Country
United States
Facility Name
Novartis Investigative Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77021
Country
United States
Facility Name
Novartis Investigative Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Novartis Investigative Site
City
Everett
State/Province
Washington
ZIP/Postal Code
98208
Country
United States
Facility Name
Novartis Investigative Site
City
Kirkland
State/Province
Washington
ZIP/Postal Code
98034
Country
United States
Facility Name
Novartis Investigative Site
City
Bahia Blanca
State/Province
Buenos Aires
ZIP/Postal Code
8000
Country
Argentina
Facility Name
Novartis Investigative Site
City
Caba
State/Province
Buenos Aires
ZIP/Postal Code
C1180AAX
Country
Argentina
Facility Name
Novartis Investigative Site
City
Caba
State/Province
Buenos Aires
ZIP/Postal Code
C1408INH
Country
Argentina
Facility Name
Novartis Investigative Site
City
Caba
State/Province
Buenos Aires
ZIP/Postal Code
C1416DRJ
Country
Argentina
Facility Name
Novartis Investigative Site
City
Coronel Suarez
State/Province
Buenos Aires
ZIP/Postal Code
B7540GHD
Country
Argentina
Facility Name
Novartis Investigative Site
City
La Plata
State/Province
Buenos Aires
ZIP/Postal Code
1900
Country
Argentina
Facility Name
Novartis Investigative Site
City
Quilmes
State/Province
Buenos Aires
ZIP/Postal Code
B1878GEG
Country
Argentina
Facility Name
Novartis Investigative Site
City
Ramos Mejia
State/Province
Buenos Aires
ZIP/Postal Code
B1704ETD
Country
Argentina
Facility Name
Novartis Investigative Site
City
San Isidro
State/Province
Buenos Aires
ZIP/Postal Code
B1642DCD
Country
Argentina
Facility Name
Novartis Investigative Site
City
San Nicolas
State/Province
Buenos Aires
ZIP/Postal Code
B2900DMH
Country
Argentina
Facility Name
Novartis Investigative Site
City
Córdoba
State/Province
Cordoba
ZIP/Postal Code
X5152HQC
Country
Argentina
Facility Name
Novartis Investigative Site
City
Va Allende
State/Province
Cordoba
ZIP/Postal Code
5105
Country
Argentina
Facility Name
Novartis Investigative Site
City
Villa Maria
State/Province
Cordoba
ZIP/Postal Code
X5220XAO
Country
Argentina
Facility Name
Novartis Investigative Site
City
Posadas
State/Province
Misiones
ZIP/Postal Code
N3300AHX
Country
Argentina
Facility Name
Novartis Investigative Site
City
Tucuman
State/Province
San Miguel de Tucuman
ZIP/Postal Code
T4000ICL
Country
Argentina
Facility Name
Novartis Investigative Site
City
Rosario
State/Province
Santa Fe
ZIP/Postal Code
S2000CXH
Country
Argentina
Facility Name
Novartis Investigative Site
City
Rosario
State/Province
Santa Fe
ZIP/Postal Code
S2000DFD
Country
Argentina
Facility Name
Novartis Investigative Site
City
Rosario
State/Province
Santa Fe
ZIP/Postal Code
S2000DSV
Country
Argentina
Facility Name
Novartis Investigative Site
City
Rosario
State/Province
Santa Fe
ZIP/Postal Code
S2001ODA
Country
Argentina
Facility Name
Novartis Investigative Site
City
San Miguel de Tucuman
State/Province
Tucuman
ZIP/Postal Code
T4000IFL
Country
Argentina
Facility Name
Novartis Investigative Site
City
Buenos Aires
ZIP/Postal Code
C1094AAD
Country
Argentina
Facility Name
Novartis Investigative Site
City
Buenos Aires
ZIP/Postal Code
C1428DCO
Country
Argentina
Facility Name
Novartis Investigative Site
City
Cordoba
ZIP/Postal Code
X5000AAI
Country
Argentina
Facility Name
Novartis Investigative Site
City
Cordoba
ZIP/Postal Code
X5000AVI
Country
Argentina
Facility Name
Novartis Investigative Site
City
Cordoba
ZIP/Postal Code
X5000EPU
Country
Argentina
Facility Name
Novartis Investigative Site
City
Cordoba
ZIP/Postal Code
X5000EVQ
Country
Argentina
Facility Name
Novartis Investigative Site
City
Cordoba
ZIP/Postal Code
X5000FGG
Country
Argentina
Facility Name
Novartis Investigative Site
City
Cordoba
ZIP/Postal Code
X5002AOQ
Country
Argentina
Facility Name
Novartis Investigative Site
City
Cordoba
ZIP/Postal Code
X5003DCE
Country
Argentina
Facility Name
Novartis Investigative Site
City
Cordoba
ZIP/Postal Code
X5004BAL
Country
Argentina
Facility Name
Novartis Investigative Site
City
Cordoba
ZIP/Postal Code
X5006IKK
Country
Argentina
Facility Name
Novartis Investigative Site
City
Cordoba
ZIP/Postal Code
X5009BSN
Country
Argentina
Facility Name
Novartis Investigative Site
City
Cordoba
ZIP/Postal Code
X5022CPU
Country
Argentina
Facility Name
Novartis Investigative Site
City
Cordoba
ZIP/Postal Code
X5220XAO
Country
Argentina
Facility Name
Novartis Investigative Site
City
Corrientes
ZIP/Postal Code
W3400CBI
Country
Argentina
Facility Name
Novartis Investigative Site
City
Corrientes
ZIP/Postal Code
W3400
Country
Argentina
Facility Name
Novartis Investigative Site
City
Salta
ZIP/Postal Code
4400
Country
Argentina
Facility Name
Novartis Investigative Site
City
Canberra
State/Province
Australian Capital Territory
ZIP/Postal Code
2605
Country
Australia
Facility Name
Novartis Investigative Site
City
Darlinghurst
State/Province
New South Wales
ZIP/Postal Code
2010
Country
Australia
Facility Name
Novartis Investigative Site
City
Kingswood
State/Province
New South Wales
ZIP/Postal Code
2747
Country
Australia
Facility Name
Novartis Investigative Site
City
Wollongong
State/Province
New South Wales
ZIP/Postal Code
2500
Country
Australia
Facility Name
Novartis Investigative Site
City
Auchenflower
State/Province
Queensland
ZIP/Postal Code
4066
Country
Australia
Facility Name
Novartis Investigative Site
City
Woolloongabba
State/Province
Queensland
ZIP/Postal Code
4101
Country
Australia
Facility Name
Novartis Investigative Site
City
Wooloongabba
State/Province
Queensland
ZIP/Postal Code
4102
Country
Australia
Facility Name
Novartis Investigative Site
City
Bedford Park
State/Province
South Australia
ZIP/Postal Code
5042
Country
Australia
Facility Name
Novartis Investigative Site
City
Launceston
State/Province
Tasmania
ZIP/Postal Code
7250
Country
Australia
Facility Name
Novartis Investigative Site
City
Geelong
State/Province
Victoria
ZIP/Postal Code
3220
Country
Australia
Facility Name
Novartis Investigative Site
City
Prahran
State/Province
Victoria
ZIP/Postal Code
3181
Country
Australia
Facility Name
Novartis Investigative Site
City
Innsbruck
State/Province
Tyrol
ZIP/Postal Code
6020
Country
Austria
Facility Name
Novartis Investigative Site
City
Graz
ZIP/Postal Code
A-8036
Country
Austria
Facility Name
Novartis Investigative Site
City
Linz
ZIP/Postal Code
4010
Country
Austria
Facility Name
Novartis Investigative Site
City
Linz
ZIP/Postal Code
A-4010
Country
Austria
Facility Name
Novartis Investigative Site
City
Salzburg
ZIP/Postal Code
A-5020
Country
Austria
Facility Name
Novartis Investigative Site
City
Vienna
ZIP/Postal Code
1030
Country
Austria
Facility Name
Novartis Investigative Site
City
Vienna
ZIP/Postal Code
1140
Country
Austria
Facility Name
Novartis Investigative Site
City
Wien
ZIP/Postal Code
A-1090
Country
Austria
Facility Name
Novartis Investigative Site
City
Wien
ZIP/Postal Code
A-1160
Country
Austria
Facility Name
Novartis Investigative Site
City
Anderlecht
ZIP/Postal Code
1070
Country
Belgium
Facility Name
Novartis Investigative Site
City
Brugge
ZIP/Postal Code
8000
Country
Belgium
Facility Name
Novartis Investigative Site
City
Brussels
ZIP/Postal Code
1180
Country
Belgium
Facility Name
Novartis Investigative Site
City
Bruxelles
ZIP/Postal Code
1200
Country
Belgium
Facility Name
Novartis Investigative Site
City
De Pinte
ZIP/Postal Code
9840
Country
Belgium
Facility Name
Novartis Investigative Site
City
Eupen
ZIP/Postal Code
4700
Country
Belgium
Facility Name
Novartis Investigative Site
City
Genk
ZIP/Postal Code
3600
Country
Belgium
Facility Name
Novartis Investigative Site
City
Huy
ZIP/Postal Code
4500
Country
Belgium
Facility Name
Novartis Investigative Site
City
Ieper
ZIP/Postal Code
8900
Country
Belgium
Facility Name
Novartis Investigative Site
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Name
Novartis Investigative Site
City
Liege
ZIP/Postal Code
4000
Country
Belgium
Facility Name
Novartis Investigative Site
City
Turnhout
ZIP/Postal Code
2300
Country
Belgium
Facility Name
Novartis Investigative Site
City
Fortaleza
State/Province
CE
ZIP/Postal Code
60864-190
Country
Brazil
Facility Name
Novartis Investigative Site
City
Brasilia
State/Province
DF
ZIP/Postal Code
70658-700
Country
Brazil
Facility Name
Novartis Investigative Site
City
Goiania
State/Province
GO
ZIP/Postal Code
74605-050
Country
Brazil
Facility Name
Novartis Investigative Site
City
Belo Horizonte
State/Province
MG
ZIP/Postal Code
30110-934
Country
Brazil
Facility Name
Novartis Investigative Site
City
Belo Horizonte
State/Province
MG
Country
Brazil
Facility Name
Novartis Investigative Site
City
Recife
State/Province
PE
ZIP/Postal Code
50100-060
Country
Brazil
Facility Name
Novartis Investigative Site
City
Campina Grande do Sul
State/Province
PR
ZIP/Postal Code
83430-000
Country
Brazil
Facility Name
Novartis Investigative Site
City
Curitiba
State/Province
PR
ZIP/Postal Code
80010-030
Country
Brazil
Facility Name
Novartis Investigative Site
City
Londrina
State/Province
PR
ZIP/Postal Code
86051-990
Country
Brazil
Facility Name
Novartis Investigative Site
City
Rio de Janeiro
State/Province
RJ
ZIP/Postal Code
22240-006
Country
Brazil
Facility Name
Novartis Investigative Site
City
Caxias do Sul
State/Province
RS
ZIP/Postal Code
95070-560
Country
Brazil
Facility Name
Novartis Investigative Site
City
Porto Alegre
State/Province
RS
ZIP/Postal Code
90020-090
Country
Brazil
Facility Name
Novartis Investigative Site
City
Porto Alegre
State/Province
RS
ZIP/Postal Code
90035-903
Country
Brazil
Facility Name
Novartis Investigative Site
City
Porto Alegre
State/Province
RS
ZIP/Postal Code
90560-030
Country
Brazil
Facility Name
Novartis Investigative Site
City
Porto Alegre
State/Province
RS
ZIP/Postal Code
90610-000
Country
Brazil
Facility Name
Novartis Investigative Site
City
Campinas
State/Province
SP
ZIP/Postal Code
13020-431
Country
Brazil
Facility Name
Novartis Investigative Site
City
Campinas
State/Province
SP
ZIP/Postal Code
13060-904
Country
Brazil
Facility Name
Novartis Investigative Site
City
Campinas
State/Province
SP
ZIP/Postal Code
13083-190
Country
Brazil
Facility Name
Novartis Investigative Site
City
Marilia
State/Province
SP
ZIP/Postal Code
17519-030
Country
Brazil
Facility Name
Novartis Investigative Site
City
São Paulo
State/Province
SP
ZIP/Postal Code
05403-900
Country
Brazil
Facility Name
Novartis Investigative Site
City
Tatuí
State/Province
SP
ZIP/Postal Code
18270-170
Country
Brazil
Facility Name
Novartis Investigative Site
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2N 4Z6
Country
Canada
Facility Name
Novartis Investigative Site
City
St. John
State/Province
New Brunswick
ZIP/Postal Code
E2L 4L2
Country
Canada
Facility Name
Novartis Investigative Site
City
Brampton
State/Province
Ontario
ZIP/Postal Code
L6Z 4N5
Country
Canada
Facility Name
Novartis Investigative Site
City
Cambridge
State/Province
Ontario
ZIP/Postal Code
N1R 6V6
Country
Canada
Facility Name
Novartis Investigative Site
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1Y 4W7
Country
Canada
Facility Name
Novartis Investigative Site
City
Joliette
State/Province
Quebec
ZIP/Postal Code
J6E 6J2
Country
Canada
Facility Name
Novartis Investigative Site
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H1T 1C8
Country
Canada
Facility Name
Novartis Investigative Site
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H1T 3Y7
Country
Canada
Facility Name
Novartis Investigative Site
City
Québec
State/Province
Quebec
ZIP/Postal Code
G1J 1Z6
Country
Canada
Facility Name
Novartis Investigative Site
City
Sainte-Foy
State/Province
Quebec
ZIP/Postal Code
G1V 4G5
Country
Canada
Facility Name
Novartis Investigative Site
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100083
Country
China
Facility Name
Novartis Investigative Site
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100088
Country
China
Facility Name
Novartis Investigative Site
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100730
Country
China
Facility Name
Novartis Investigative Site
City
Fuzhou
State/Province
Fujian
ZIP/Postal Code
350001
Country
China
Facility Name
Novartis Investigative Site
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510080
Country
China
Facility Name
Novartis Investigative Site
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510515
Country
China
Facility Name
Novartis Investigative Site
City
Shijiazhuang
State/Province
Hebei
ZIP/Postal Code
050000
Country
China
Facility Name
Novartis Investigative Site
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430022
Country
China
Facility Name
Novartis Investigative Site
City
Nanjing
State/Province
Jiangsu
Country
China
Facility Name
Novartis Investigative Site
City
Suzhou
State/Province
Jiangsu
ZIP/Postal Code
215004
Country
China
Facility Name
Novartis Investigative Site
City
Changchun
State/Province
Jilin
ZIP/Postal Code
130021
Country
China
Facility Name
Novartis Investigative Site
City
Shenyang
State/Province
Liaoning
ZIP/Postal Code
110003
Country
China
Facility Name
Novartis Investigative Site
City
Shenyang
State/Province
Liaoning
ZIP/Postal Code
110016
Country
China
Facility Name
Novartis Investigative Site
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200011
Country
China
Facility Name
Novartis Investigative Site
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300121
Country
China
Facility Name
Novartis Investigative Site
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310006
Country
China
Facility Name
Novartis Investigative Site
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310009
Country
China
Facility Name
Novartis Investigative Site
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310013
Country
China
Facility Name
Novartis Investigative Site
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310016
Country
China
Facility Name
Novartis Investigative Site
City
Baotou
ZIP/Postal Code
014040
Country
China
Facility Name
Novartis Investigative Site
City
Beijing
ZIP/Postal Code
100020
Country
China
Facility Name
Novartis Investigative Site
City
Beijing
ZIP/Postal Code
100028
Country
China
Facility Name
Novartis Investigative Site
City
Beijing
ZIP/Postal Code
100029
Country
China
Facility Name
Novartis Investigative Site
City
Beijing
ZIP/Postal Code
100034
Country
China
Facility Name
Novartis Investigative Site
City
Beijing
ZIP/Postal Code
100044
Country
China
Facility Name
Novartis Investigative Site
City
Beijing
ZIP/Postal Code
100050
Country
China
Facility Name
Novartis Investigative Site
City
Guang zhou
ZIP/Postal Code
510080
Country
China
Facility Name
Novartis Investigative Site
City
Jinan
ZIP/Postal Code
250012
Country
China
Facility Name
Novartis Investigative Site
City
Shanghai
ZIP/Postal Code
200025
Country
China
Facility Name
Novartis Investigative Site
City
Shanghai
ZIP/Postal Code
200032
Country
China
Facility Name
Novartis Investigative Site
City
Shanghai
ZIP/Postal Code
200233
Country
China
Facility Name
Novartis Investigative Site
City
Tianjin
ZIP/Postal Code
300142
Country
China
Facility Name
Novartis Investigative Site
City
Xian
ZIP/Postal Code
710004
Country
China
Facility Name
Novartis Investigative Site
City
Medellín
State/Province
Antioquia
Country
Colombia
Facility Name
Novartis Investigative Site
City
Baranquilla
State/Province
Atlantico
Country
Colombia
Facility Name
Novartis Investigative Site
City
Barranquilla
State/Province
Atlantico
Country
Colombia
Facility Name
Novartis Investigative Site
City
Cartagena
State/Province
Bolivar
Country
Colombia
Facility Name
Novartis Investigative Site
City
Bogota
State/Province
Cundinamarca
ZIP/Postal Code
111411
Country
Colombia
Facility Name
Novartis Investigative Site
City
Bogotá
State/Province
Cundinamarca
ZIP/Postal Code
110111
Country
Colombia
Facility Name
Novartis Investigative Site
City
Barranquilla
Country
Colombia
Facility Name
Novartis Investigative Site
City
Bogotá
ZIP/Postal Code
00000
Country
Colombia
Facility Name
Novartis Investigative Site
City
Bogotá
Country
Colombia
Facility Name
Novartis Investigative Site
City
Florida Blanca
Country
Colombia
Facility Name
Novartis Investigative Site
City
Medellín
Country
Colombia
Facility Name
Novartis Investigative Site
City
Goicoechea
State/Province
San Jose, Costa Rica
ZIP/Postal Code
3184-1000
Country
Costa Rica
Facility Name
Novartis Investigative Site
City
Alajuela
Country
Costa Rica
Facility Name
Novartis Investigative Site
City
San Jose
ZIP/Postal Code
1307-1000
Country
Costa Rica
Facility Name
Novartis Investigative Site
City
San Jose
ZIP/Postal Code
272-1225
Country
Costa Rica
Facility Name
Novartis Investigative Site
City
Benesov
ZIP/Postal Code
25601
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Brno
ZIP/Postal Code
60200
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Cesky Krumlov
ZIP/Postal Code
381 01
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Jindrichuv Hradec
ZIP/Postal Code
377 01
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Kolín
ZIP/Postal Code
280 02
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Kromeriz
ZIP/Postal Code
767 01
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Louny
ZIP/Postal Code
440 01
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Louny
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Marianske lazne
ZIP/Postal Code
353 01
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Ostrava
ZIP/Postal Code
70200
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Plzen
ZIP/Postal Code
323 00
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Praha 11
ZIP/Postal Code
148 00
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Praha 2
ZIP/Postal Code
128 08
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Praha 9
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Pribram VIII
ZIP/Postal Code
261 01
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Teplice
ZIP/Postal Code
415 01
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Vyskov
ZIP/Postal Code
68001
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Aalborg
ZIP/Postal Code
DK-9000
Country
Denmark
Facility Name
Novartis Investigative Site
City
Copenhagen NV
ZIP/Postal Code
DK-2400
Country
Denmark
Facility Name
Novartis Investigative Site
City
Copenhagen S
ZIP/Postal Code
DK-2300
Country
Denmark
Facility Name
Novartis Investigative Site
City
Copenhagen
ZIP/Postal Code
2100
Country
Denmark
Facility Name
Novartis Investigative Site
City
Esbjerg
ZIP/Postal Code
DK-6700
Country
Denmark
Facility Name
Novartis Investigative Site
City
Fredericia
ZIP/Postal Code
7000
Country
Denmark
Facility Name
Novartis Investigative Site
City
Frederiksberg
ZIP/Postal Code
DK-2000
Country
Denmark
Facility Name
Novartis Investigative Site
City
Glostrup
ZIP/Postal Code
DK-2600
Country
Denmark
Facility Name
Novartis Investigative Site
City
Hellerup
ZIP/Postal Code
DK-2900
Country
Denmark
Facility Name
Novartis Investigative Site
City
Helsingoer
ZIP/Postal Code
DK-3000
Country
Denmark
Facility Name
Novartis Investigative Site
City
Hillerød
ZIP/Postal Code
DK-3400
Country
Denmark
Facility Name
Novartis Investigative Site
City
Hjørring
ZIP/Postal Code
DK-9800
Country
Denmark
Facility Name
Novartis Investigative Site
City
Holbæk
ZIP/Postal Code
DK-4300
Country
Denmark
Facility Name
Novartis Investigative Site
City
Hvidovre
ZIP/Postal Code
DK-2650
Country
Denmark
Facility Name
Novartis Investigative Site
City
Køge
ZIP/Postal Code
DK-4600
Country
Denmark
Facility Name
Novartis Investigative Site
City
Næstved
ZIP/Postal Code
DK-4700
Country
Denmark
Facility Name
Novartis Investigative Site
City
Odense C
ZIP/Postal Code
DK-5000
Country
Denmark
Facility Name
Novartis Investigative Site
City
Randers NØ
ZIP/Postal Code
DK-8930
Country
Denmark
Facility Name
Novartis Investigative Site
City
Silkeborg
ZIP/Postal Code
8600
Country
Denmark
Facility Name
Novartis Investigative Site
City
Svendborg
ZIP/Postal Code
DK-5700
Country
Denmark
Facility Name
Novartis Investigative Site
City
Viborg
ZIP/Postal Code
DK-8800
Country
Denmark
Facility Name
Novartis Investigative Site
City
Århus N
ZIP/Postal Code
DK-8200
Country
Denmark
Facility Name
Novartis Investigative Site
City
Santo Domingo
State/Province
Republica Dominicana
Country
Dominican Republic
Facility Name
Novartis Investigative Site
City
San Cristobal
Country
Dominican Republic
Facility Name
Novartis Investigative Site
City
Parnu
ZIP/Postal Code
80010
Country
Estonia
Facility Name
Novartis Investigative Site
City
Tallinn
ZIP/Postal Code
10138
Country
Estonia
Facility Name
Novartis Investigative Site
City
Tallinn
ZIP/Postal Code
13419
Country
Estonia
Facility Name
Novartis Investigative Site
City
Tartu
ZIP/Postal Code
51014
Country
Estonia
Facility Name
Novartis Investigative Site
City
Hyvinkää
ZIP/Postal Code
FIN-05850
Country
Finland
Facility Name
Novartis Investigative Site
City
Jyvaskyla
ZIP/Postal Code
FIN-40620
Country
Finland
Facility Name
Novartis Investigative Site
City
Seinajoki
ZIP/Postal Code
60200
Country
Finland
Facility Name
Novartis Investigative Site
City
Tammisaari
ZIP/Postal Code
10600
Country
Finland
Facility Name
Novartis Investigative Site
City
Turku
ZIP/Postal Code
FIN-20520
Country
Finland
Facility Name
Novartis Investigative Site
City
Albi
ZIP/Postal Code
81013
Country
France
Facility Name
Novartis Investigative Site
City
Angers
ZIP/Postal Code
49000
Country
France
Facility Name
Novartis Investigative Site
City
Becon Les Granits
ZIP/Postal Code
49370
Country
France
Facility Name
Novartis Investigative Site
City
Clichy
ZIP/Postal Code
92110
Country
France
Facility Name
Novartis Investigative Site
City
Dijon
ZIP/Postal Code
21079
Country
France
Facility Name
Novartis Investigative Site
City
Grenoble
ZIP/Postal Code
38043
Country
France
Facility Name
Novartis Investigative Site
City
Marseille Cedex 05
ZIP/Postal Code
13385
Country
France
Facility Name
Novartis Investigative Site
City
Marseille
ZIP/Postal Code
13915
Country
France
Facility Name
Novartis Investigative Site
City
Paris
ZIP/Postal Code
75013
Country
France
Facility Name
Novartis Investigative Site
City
Paris
ZIP/Postal Code
75571
Country
France
Facility Name
Novartis Investigative Site
City
Pessac Cedex
ZIP/Postal Code
33604
Country
France
Facility Name
Novartis Investigative Site
City
Saint-Etienne
ZIP/Postal Code
42055
Country
France
Facility Name
Novartis Investigative Site
City
Vandoeuvre Les Nancy
ZIP/Postal Code
54511
Country
France
Facility Name
Novartis Investigative Site
City
Winsen (Luhe)
State/Province
Lower Saxony
ZIP/Postal Code
21423
Country
Germany
Facility Name
Novartis Investigative Site
City
Augsburg
ZIP/Postal Code
86150
Country
Germany
Facility Name
Novartis Investigative Site
City
Bad Nauheim
ZIP/Postal Code
61231
Country
Germany
Facility Name
Novartis Investigative Site
City
Bad Neustadt an der Saale
ZIP/Postal Code
97616
Country
Germany
Facility Name
Novartis Investigative Site
City
Bensheim
ZIP/Postal Code
64625
Country
Germany
Facility Name
Novartis Investigative Site
City
Berlin
ZIP/Postal Code
10367
Country
Germany
Facility Name
Novartis Investigative Site
City
Berlin
ZIP/Postal Code
10789
Country
Germany
Facility Name
Novartis Investigative Site
City
Berlin
ZIP/Postal Code
12163
Country
Germany
Facility Name
Novartis Investigative Site
City
Berlin
ZIP/Postal Code
12351
Country
Germany
Facility Name
Novartis Investigative Site
City
Berlin
ZIP/Postal Code
12552
Country
Germany
Facility Name
Novartis Investigative Site
City
Berlin
ZIP/Postal Code
13353
Country
Germany
Facility Name
Novartis Investigative Site
City
Berlin
ZIP/Postal Code
13405
Country
Germany
Facility Name
Novartis Investigative Site
City
Bochum
ZIP/Postal Code
44791
Country
Germany
Facility Name
Novartis Investigative Site
City
Bonn
ZIP/Postal Code
53115
Country
Germany
Facility Name
Novartis Investigative Site
City
Bonn
ZIP/Postal Code
53127
Country
Germany
Facility Name
Novartis Investigative Site
City
Bonn
ZIP/Postal Code
53225
Country
Germany
Facility Name
Novartis Investigative Site
City
Brake
ZIP/Postal Code
26919
Country
Germany
Facility Name
Novartis Investigative Site
City
Celle
ZIP/Postal Code
29223
Country
Germany
Facility Name
Novartis Investigative Site
City
Chemnitz
ZIP/Postal Code
09113
Country
Germany
Facility Name
Novartis Investigative Site
City
Chemnitz
ZIP/Postal Code
09116
Country
Germany
Facility Name
Novartis Investigative Site
City
Chemnitz
ZIP/Postal Code
09126
Country
Germany
Facility Name
Novartis Investigative Site
City
Coburg
ZIP/Postal Code
96450
Country
Germany
Facility Name
Novartis Investigative Site
City
Darmstadt
ZIP/Postal Code
64283
Country
Germany
Facility Name
Novartis Investigative Site
City
Dessau-Roßlau
ZIP/Postal Code
06846
Country
Germany
Facility Name
Novartis Investigative Site
City
Dinkelsbühl
ZIP/Postal Code
91550
Country
Germany
Facility Name
Novartis Investigative Site
City
Dorsten
ZIP/Postal Code
46282
Country
Germany
Facility Name
Novartis Investigative Site
City
Dortmund
ZIP/Postal Code
44137
Country
Germany
Facility Name
Novartis Investigative Site
City
Dresden
ZIP/Postal Code
01067
Country
Germany
Facility Name
Novartis Investigative Site
City
Dresden
ZIP/Postal Code
01097
Country
Germany
Facility Name
Novartis Investigative Site
City
Dresden
ZIP/Postal Code
01219
Country
Germany
Facility Name
Novartis Investigative Site
City
Dresden
ZIP/Postal Code
01277
Country
Germany
Facility Name
Novartis Investigative Site
City
Dresden
ZIP/Postal Code
01309
Country
Germany
Facility Name
Novartis Investigative Site
City
Duisburg
ZIP/Postal Code
47051
Country
Germany
Facility Name
Novartis Investigative Site
City
Duisburg
ZIP/Postal Code
47139
Country
Germany
Facility Name
Novartis Investigative Site
City
Düsseldorf
ZIP/Postal Code
40593
Country
Germany
Facility Name
Novartis Investigative Site
City
Ebersbach
ZIP/Postal Code
02730
Country
Germany
Facility Name
Novartis Investigative Site
City
Erfurt
ZIP/Postal Code
99084
Country
Germany
Facility Name
Novartis Investigative Site
City
Erkner
ZIP/Postal Code
15537
Country
Germany
Facility Name
Novartis Investigative Site
City
Essen
ZIP/Postal Code
45136
Country
Germany
Facility Name
Novartis Investigative Site
City
Essen
ZIP/Postal Code
45355
Country
Germany
Facility Name
Novartis Investigative Site
City
Frankfurt
ZIP/Postal Code
60594
Country
Germany
Facility Name
Novartis Investigative Site
City
Goettingen
ZIP/Postal Code
37075
Country
Germany
Facility Name
Novartis Investigative Site
City
Gotha
ZIP/Postal Code
99867
Country
Germany
Facility Name
Novartis Investigative Site
City
Göttingen
ZIP/Postal Code
37073
Country
Germany
Facility Name
Novartis Investigative Site
City
Gütersloh
ZIP/Postal Code
33332
Country
Germany
Facility Name
Novartis Investigative Site
City
Halle (Saale)
ZIP/Postal Code
06120
Country
Germany
Facility Name
Novartis Investigative Site
City
Halle/Saale
ZIP/Postal Code
06120
Country
Germany
Facility Name
Novartis Investigative Site
City
Hamburg
ZIP/Postal Code
20099
Country
Germany
Facility Name
Novartis Investigative Site
City
Hannover
ZIP/Postal Code
30167
Country
Germany
Facility Name
Novartis Investigative Site
City
Hassloch
ZIP/Postal Code
67454
Country
Germany
Facility Name
Novartis Investigative Site
City
Heidelberg
ZIP/Postal Code
69115
Country
Germany
Facility Name
Novartis Investigative Site
City
Heidelberg
ZIP/Postal Code
69120
Country
Germany
Facility Name
Novartis Investigative Site
City
Heilbronn
ZIP/Postal Code
74078
Country
Germany
Facility Name
Novartis Investigative Site
City
Helmbrechts
ZIP/Postal Code
95223
Country
Germany
Facility Name
Novartis Investigative Site
City
Heppenheim
ZIP/Postal Code
64646
Country
Germany
Facility Name
Novartis Investigative Site
City
Kassel
ZIP/Postal Code
34127
Country
Germany
Facility Name
Novartis Investigative Site
City
Kleve
ZIP/Postal Code
47533
Country
Germany
Facility Name
Novartis Investigative Site
City
Koblenz
ZIP/Postal Code
56068
Country
Germany
Facility Name
Novartis Investigative Site
City
Krefeld
ZIP/Postal Code
47798
Country
Germany
Facility Name
Novartis Investigative Site
City
Köln
ZIP/Postal Code
51605
Country
Germany
Facility Name
Novartis Investigative Site
City
Königsbrück
ZIP/Postal Code
01436
Country
Germany
Facility Name
Novartis Investigative Site
City
Köthen
ZIP/Postal Code
06366
Country
Germany
Facility Name
Novartis Investigative Site
City
Lambrecht
ZIP/Postal Code
67466
Country
Germany
Facility Name
Novartis Investigative Site
City
Landshut
ZIP/Postal Code
84034
Country
Germany
Facility Name
Novartis Investigative Site
City
Leipzig
ZIP/Postal Code
04177
Country
Germany
Facility Name
Novartis Investigative Site
City
Lichtentanne
ZIP/Postal Code
08115
Country
Germany
Facility Name
Novartis Investigative Site
City
Lienen
ZIP/Postal Code
49536
Country
Germany
Facility Name
Novartis Investigative Site
City
Ludwigsburg
ZIP/Postal Code
71634
Country
Germany
Facility Name
Novartis Investigative Site
City
Lörrach
ZIP/Postal Code
79539
Country
Germany
Facility Name
Novartis Investigative Site
City
Lüneburg
ZIP/Postal Code
21339
Country
Germany
Facility Name
Novartis Investigative Site
City
Magdeburg
ZIP/Postal Code
39110
Country
Germany
Facility Name
Novartis Investigative Site
City
Mainz
ZIP/Postal Code
55116
Country
Germany
Facility Name
Novartis Investigative Site
City
Markkleeberg
ZIP/Postal Code
04416
Country
Germany
Facility Name
Novartis Investigative Site
City
Mayen
ZIP/Postal Code
56727
Country
Germany
Facility Name
Novartis Investigative Site
City
Melsungen
ZIP/Postal Code
34212
Country
Germany
Facility Name
Novartis Investigative Site
City
Muehldorf am Inn
ZIP/Postal Code
84453
Country
Germany
Facility Name
Novartis Investigative Site
City
Muehlheim an der Ruhr
ZIP/Postal Code
45468
Country
Germany
Facility Name
Novartis Investigative Site
City
Muenchen
ZIP/Postal Code
80636
Country
Germany
Facility Name
Novartis Investigative Site
City
Mülheim
ZIP/Postal Code
45468
Country
Germany
Facility Name
Novartis Investigative Site
City
Northeim
ZIP/Postal Code
37154
Country
Germany
Facility Name
Novartis Investigative Site
City
Nürnberg
ZIP/Postal Code
90471
Country
Germany
Facility Name
Novartis Investigative Site
City
Oelde
ZIP/Postal Code
59302
Country
Germany
Facility Name
Novartis Investigative Site
City
Oelde
ZIP/Postal Code
59303
Country
Germany
Facility Name
Novartis Investigative Site
City
Pirna
ZIP/Postal Code
01796
Country
Germany
Facility Name
Novartis Investigative Site
City
Potsdam
ZIP/Postal Code
14471
Country
Germany
Facility Name
Novartis Investigative Site
City
Reinfeld
ZIP/Postal Code
23858
Country
Germany
Facility Name
Novartis Investigative Site
City
Salzwedel
ZIP/Postal Code
29410
Country
Germany
Facility Name
Novartis Investigative Site
City
Schwalmstadt
ZIP/Postal Code
34613
Country
Germany
Facility Name
Novartis Investigative Site
City
Schwäbisch Hall
ZIP/Postal Code
74523
Country
Germany
Facility Name
Novartis Investigative Site
City
Siegen
ZIP/Postal Code
57072
Country
Germany
Facility Name
Novartis Investigative Site
City
Solingen
ZIP/Postal Code
42651
Country
Germany
Facility Name
Novartis Investigative Site
City
Stade
ZIP/Postal Code
21682
Country
Germany
Facility Name
Novartis Investigative Site
City
Stuttgart
ZIP/Postal Code
70372
Country
Germany
Facility Name
Novartis Investigative Site
City
Stuttgart
ZIP/Postal Code
70378
Country
Germany
Facility Name
Novartis Investigative Site
City
Wedel
ZIP/Postal Code
22880
Country
Germany
Facility Name
Novartis Investigative Site
City
Witten
ZIP/Postal Code
58455
Country
Germany
Facility Name
Novartis Investigative Site
City
Wuerzburg
ZIP/Postal Code
97078
Country
Germany
Facility Name
Novartis Investigative Site
City
Zwickau
ZIP/Postal Code
08056
Country
Germany
Facility Name
Novartis Investigative Site
City
Athens
State/Province
GR
ZIP/Postal Code
115 27
Country
Greece
Facility Name
Novartis Investigative Site
City
Thessaloniki
State/Province
GR
ZIP/Postal Code
546 36
Country
Greece
Facility Name
Novartis Investigative Site
City
Thessaloniki
State/Province
GR
ZIP/Postal Code
570 10
Country
Greece
Facility Name
Novartis Investigative Site
City
Athens
ZIP/Postal Code
115 28
Country
Greece
Facility Name
Novartis Investigative Site
City
Athens
ZIP/Postal Code
124 62
Country
Greece
Facility Name
Novartis Investigative Site
City
Athens
ZIP/Postal Code
GR 11527
Country
Greece
Facility Name
Novartis Investigative Site
City
Chios
ZIP/Postal Code
82100
Country
Greece
Facility Name
Novartis Investigative Site
City
Edessa
ZIP/Postal Code
58200
Country
Greece
Facility Name
Novartis Investigative Site
City
Guntur
State/Province
Andhra Pradesh
ZIP/Postal Code
522001
Country
India
Facility Name
Novartis Investigative Site
City
Hyderabad
State/Province
Andhra Pradesh
ZIP/Postal Code
500012
Country
India
Facility Name
Novartis Investigative Site
City
Secunderabad
State/Province
Andhra Pradesh
ZIP/Postal Code
500003
Country
India
Facility Name
Novartis Investigative Site
City
Vijayawada
State/Province
Andhra Pradesh
ZIP/Postal Code
520 008
Country
India
Facility Name
Novartis Investigative Site
City
New Delhi
State/Province
Delhi
ZIP/Postal Code
110060
Country
India
Facility Name
Novartis Investigative Site
City
Ahmedabad
State/Province
Gujarat
ZIP/Postal Code
380 051
Country
India
Facility Name
Novartis Investigative Site
City
Bangalore
State/Province
Karnataka
ZIP/Postal Code
560 052
Country
India
Facility Name
Novartis Investigative Site
City
Bangalore
State/Province
Karnataka
ZIP/Postal Code
560099
Country
India
Facility Name
Novartis Investigative Site
City
Manipal
State/Province
Karnataka
ZIP/Postal Code
576104
Country
India
Facility Name
Novartis Investigative Site
City
Trivandrum
State/Province
Kerela
ZIP/Postal Code
695002
Country
India
Facility Name
Novartis Investigative Site
City
Mumbai
State/Province
Maharashtra
ZIP/Postal Code
400 022
Country
India
Facility Name
Novartis Investigative Site
City
Nagpur
State/Province
Maharashtra
ZIP/Postal Code
400 008
Country
India
Facility Name
Novartis Investigative Site
City
Nagpur
State/Province
Maharashtra
ZIP/Postal Code
400 012
Country
India
Facility Name
Novartis Investigative Site
City
Nagpur
State/Province
Maharashtra
ZIP/Postal Code
400012
Country
India
Facility Name
Novartis Investigative Site
City
Nagpur
State/Province
Maharashtra
ZIP/Postal Code
440 010
Country
India
Facility Name
Novartis Investigative Site
City
Nagpur
State/Province
Maharashtra
ZIP/Postal Code
440010
Country
India
Facility Name
Novartis Investigative Site
City
Nagpur
State/Province
Maharashtra
ZIP/Postal Code
440012
Country
India
Facility Name
Novartis Investigative Site
City
Pune
State/Province
Maharashtra
ZIP/Postal Code
411 011
Country
India
Facility Name
Novartis Investigative Site
City
Pune
State/Province
Maharashtra
ZIP/Postal Code
411 019
Country
India
Facility Name
Novartis Investigative Site
City
Pune
State/Province
Maharashtra
ZIP/Postal Code
411 044
Country
India
Facility Name
Novartis Investigative Site
City
Pune
State/Province
Maharashtra
ZIP/Postal Code
411004
Country
India
Facility Name
Novartis Investigative Site
City
Pune
State/Province
Maharashtra
ZIP/Postal Code
411011
Country
India
Facility Name
Novartis Investigative Site
City
Delhi
State/Province
New Delhi
ZIP/Postal Code
110065
Country
India
Facility Name
Novartis Investigative Site
City
Jaipur
State/Province
Rajasthan
ZIP/Postal Code
302001
Country
India
Facility Name
Novartis Investigative Site
City
Jaipur
State/Province
Rajasthan
ZIP/Postal Code
302024
Country
India
Facility Name
Novartis Investigative Site
City
Chennai
State/Province
Tamil Nadu
ZIP/Postal Code
600100
Country
India
Facility Name
Novartis Investigative Site
City
Coimbatore
State/Province
Tamil Nadu
ZIP/Postal Code
641014
Country
India
Facility Name
Novartis Investigative Site
City
Madurai
State/Province
Tamil Nadu
ZIP/Postal Code
625107
Country
India
Facility Name
Novartis Investigative Site
City
Hyderabad
State/Province
Telangana
ZIP/Postal Code
500082
Country
India
Facility Name
Novartis Investigative Site
City
Lucknow
State/Province
Uttar Pradesh
ZIP/Postal Code
226005
Country
India
Facility Name
Novartis Investigative Site
City
Lucknow
State/Province
Uttar Pradesh
ZIP/Postal Code
226014
Country
India
Facility Name
Novartis Investigative Site
City
Bangalore
ZIP/Postal Code
560 034
Country
India
Facility Name
Novartis Investigative Site
City
Hyderabad
ZIP/Postal Code
500 063
Country
India
Facility Name
Novartis Investigative Site
City
Hyderabad
ZIP/Postal Code
500044
Country
India
Facility Name
Novartis Investigative Site
City
Lucknow
ZIP/Postal Code
226003
Country
India
Facility Name
Novartis Investigative Site
City
Mumbai
ZIP/Postal Code
400 050
Country
India
Facility Name
Novartis Investigative Site
City
New Delhi
ZIP/Postal Code
110044
Country
India
Facility Name
Novartis Investigative Site
City
Noida
ZIP/Postal Code
201301
Country
India
Facility Name
Novartis Investigative Site
City
Co Dublin
Country
Ireland
Facility Name
Novartis Investigative Site
City
Dublin 7
Country
Ireland
Facility Name
Novartis Investigative Site
City
Dublin
ZIP/Postal Code
9
Country
Ireland
Facility Name
Novartis Investigative Site
City
Dublin
Country
Ireland
Facility Name
Novartis Investigative Site
City
Galway
Country
Ireland
Facility Name
Novartis Investigative Site
City
Montescano
State/Province
(pv)
ZIP/Postal Code
27040
Country
Italy
Facility Name
Novartis Investigative Site
City
Pavia
State/Province
(pv)
ZIP/Postal Code
27100
Country
Italy
Facility Name
Novartis Investigative Site
City
Ancona
State/Province
AN
ZIP/Postal Code
60126
Country
Italy
Facility Name
Novartis Investigative Site
City
Arezzo
State/Province
AR
ZIP/Postal Code
52100
Country
Italy
Facility Name
Novartis Investigative Site
City
Cortona
State/Province
AR
ZIP/Postal Code
52044
Country
Italy
Facility Name
Novartis Investigative Site
City
Bergamo
State/Province
BG
ZIP/Postal Code
24128
Country
Italy
Facility Name
Novartis Investigative Site
City
Bologna
State/Province
BO
ZIP/Postal Code
40138
Country
Italy
Facility Name
Novartis Investigative Site
City
Brescia
State/Province
BS
ZIP/Postal Code
25123
Country
Italy
Facility Name
Novartis Investigative Site
City
Lumezzane
State/Province
BS
ZIP/Postal Code
25065
Country
Italy
Facility Name
Novartis Investigative Site
City
Chieti
State/Province
CH
ZIP/Postal Code
66100
Country
Italy
Facility Name
Novartis Investigative Site
City
Cosenza
State/Province
CS
ZIP/Postal Code
87100
Country
Italy
Facility Name
Novartis Investigative Site
City
Forlì
State/Province
FC
ZIP/Postal Code
47100
Country
Italy
Facility Name
Novartis Investigative Site
City
Cona
State/Province
FE
ZIP/Postal Code
44100
Country
Italy
Facility Name
Novartis Investigative Site
City
Foggia
State/Province
FG
ZIP/Postal Code
71100
Country
Italy
Facility Name
Novartis Investigative Site
City
Firenze
State/Province
FI
ZIP/Postal Code
50143
Country
Italy
Facility Name
Novartis Investigative Site
City
Pozzilli
State/Province
IS
ZIP/Postal Code
86077
Country
Italy
Facility Name
Novartis Investigative Site
City
Casarano
State/Province
LE
ZIP/Postal Code
73042
Country
Italy
Facility Name
Novartis Investigative Site
City
Cecina
State/Province
LI
ZIP/Postal Code
57023
Country
Italy
Facility Name
Novartis Investigative Site
City
Castelnuovo di Garfagnana
State/Province
LU
ZIP/Postal Code
55032
Country
Italy
Facility Name
Novartis Investigative Site
City
Milano
State/Province
MI
ZIP/Postal Code
20132
Country
Italy
Facility Name
Novartis Investigative Site
City
Milano
State/Province
MI
ZIP/Postal Code
20138
Country
Italy
Facility Name
Novartis Investigative Site
City
Passirana di Rho
State/Province
MI
ZIP/Postal Code
20017
Country
Italy
Facility Name
Novartis Investigative Site
City
Pieve di Coriano
State/Province
MN
Country
Italy
Facility Name
Novartis Investigative Site
City
Massa
State/Province
MS
ZIP/Postal Code
54100
Country
Italy
Facility Name
Novartis Investigative Site
City
Palermo
State/Province
PA
ZIP/Postal Code
90127
Country
Italy
Facility Name
Novartis Investigative Site
City
Perugia
State/Province
PG
ZIP/Postal Code
06129
Country
Italy
Facility Name
Novartis Investigative Site
City
Parma
State/Province
PR
ZIP/Postal Code
43100
Country
Italy
Facility Name
Novartis Investigative Site
City
Pavia
State/Province
PV
ZIP/Postal Code
27100
Country
Italy
Facility Name
Novartis Investigative Site
City
Cotignola
State/Province
RA
ZIP/Postal Code
48010
Country
Italy
Facility Name
Novartis Investigative Site
City
Roma
State/Province
RM
ZIP/Postal Code
00169
Country
Italy
Facility Name
Novartis Investigative Site
City
Roma
State/Province
RM
ZIP/Postal Code
00184
Country
Italy
Facility Name
Novartis Investigative Site
City
Roma
State/Province
RM
ZIP/Postal Code
00189
Country
Italy
Facility Name
Novartis Investigative Site
City
Rimini
State/Province
RN
ZIP/Postal Code
47900
Country
Italy
Facility Name
Novartis Investigative Site
City
Cava De' Tirreni
State/Province
SA
ZIP/Postal Code
84013
Country
Italy
Facility Name
Novartis Investigative Site
City
Poggibonsi
State/Province
SI
ZIP/Postal Code
53036
Country
Italy
Facility Name
Novartis Investigative Site
City
Sondalo
State/Province
SO
ZIP/Postal Code
23035
Country
Italy
Facility Name
Novartis Investigative Site
City
Sarzana
State/Province
SP
ZIP/Postal Code
19038
Country
Italy
Facility Name
Novartis Investigative Site
City
Sassari
State/Province
SS
ZIP/Postal Code
07100
Country
Italy
Facility Name
Novartis Investigative Site
City
Orbassano
State/Province
TO
ZIP/Postal Code
10043
Country
Italy
Facility Name
Novartis Investigative Site
City
Torino
State/Province
TO
ZIP/Postal Code
10126
Country
Italy
Facility Name
Novartis Investigative Site
City
Terni
State/Province
TR
ZIP/Postal Code
05100
Country
Italy
Facility Name
Novartis Investigative Site
City
Trieste
State/Province
TS
ZIP/Postal Code
34142
Country
Italy
Facility Name
Novartis Investigative Site
City
Trieste
State/Province
TS
ZIP/Postal Code
34149
Country
Italy
Facility Name
Novartis Investigative Site
City
Vittorio Veneto
State/Province
TV
ZIP/Postal Code
31029
Country
Italy
Facility Name
Novartis Investigative Site
City
San Daniele Del Friuli
State/Province
UD
ZIP/Postal Code
33038
Country
Italy
Facility Name
Novartis Investigative Site
City
Udine
State/Province
UD
ZIP/Postal Code
33100
Country
Italy
Facility Name
Novartis Investigative Site
City
Tradate
State/Province
VA
ZIP/Postal Code
21049
Country
Italy
Facility Name
Novartis Investigative Site
City
San Bonifacio
State/Province
VR
ZIP/Postal Code
37047
Country
Italy
Facility Name
Novartis Investigative Site
City
Nagoya-city
State/Province
Aichi
ZIP/Postal Code
466-8560
Country
Japan
Facility Name
Novartis Investigative Site
City
Seto-city
State/Province
Aichi
ZIP/Postal Code
489-8642
Country
Japan
Facility Name
Novartis Investigative Site
City
Chiba-city
State/Province
Chiba
ZIP/Postal Code
260-8677
Country
Japan
Facility Name
Novartis Investigative Site
City
Inba-gun
State/Province
Chiba
ZIP/Postal Code
270-1694
Country
Japan
Facility Name
Novartis Investigative Site
City
Chikushino-city
State/Province
Fukuoka
ZIP/Postal Code
818-8502
Country
Japan
Facility Name
Novartis Investigative Site
City
Fukuoka-city
State/Province
Fukuoka
ZIP/Postal Code
814-0180
Country
Japan
Facility Name
Novartis Investigative Site
City
Iizuka-city
State/Province
Fukuoka
ZIP/Postal Code
820-8505
Country
Japan
Facility Name
Novartis Investigative Site
City
Kurume-city
State/Province
Fukuoka
ZIP/Postal Code
830-8577
Country
Japan
Facility Name
Novartis Investigative Site
City
Ogaki-city
State/Province
Gifu
ZIP/Postal Code
503-8502
Country
Japan
Facility Name
Novartis Investigative Site
City
Hiroshima-city
State/Province
Hiroshima
ZIP/Postal Code
734-8551
Country
Japan
Facility Name
Novartis Investigative Site
City
Kure
State/Province
Hiroshima
ZIP/Postal Code
737-0023
Country
Japan
Facility Name
Novartis Investigative Site
City
Sapporo-city
State/Province
Hokkaido
ZIP/Postal Code
060-8648
Country
Japan
Facility Name
Novartis Investigative Site
City
Sapporo-city
State/Province
Hokkaido
ZIP/Postal Code
063-0005
Country
Japan
Facility Name
Novartis Investigative Site
City
Amagasaki-city
State/Province
Hyogo
ZIP/Postal Code
660-8550
Country
Japan
Facility Name
Novartis Investigative Site
City
Higashiibaraki-gun
State/Province
Ibaraki
ZIP/Postal Code
311-3193
Country
Japan
Facility Name
Novartis Investigative Site
City
Hitachinaka
State/Province
Ibaraki
ZIP/Postal Code
312-0057
Country
Japan
Facility Name
Novartis Investigative Site
City
Tsukuba-city
State/Province
Ibaraki
ZIP/Postal Code
305-8576
Country
Japan
Facility Name
Novartis Investigative Site
City
Kanazawa
State/Province
Ishikawa
ZIP/Postal Code
920-8650
Country
Japan
Facility Name
Novartis Investigative Site
City
Kawasaki-city
State/Province
Kanagawa
ZIP/Postal Code
210-0852
Country
Japan
Facility Name
Novartis Investigative Site
City
Sagamihara-city
State/Province
Kanagawa
ZIP/Postal Code
252-0375
Country
Japan
Facility Name
Novartis Investigative Site
City
Yokohama-city
State/Province
Kanagawa
ZIP/Postal Code
232-0024
Country
Japan
Facility Name
Novartis Investigative Site
City
Yokosuka
State/Province
Kanagawa
ZIP/Postal Code
238-8567
Country
Japan
Facility Name
Novartis Investigative Site
City
Kumamoto City
State/Province
Kumamoto
ZIP/Postal Code
860-8556
Country
Japan
Facility Name
Novartis Investigative Site
City
Sendai-city
State/Province
Miyagi
ZIP/Postal Code
980-8574
Country
Japan
Facility Name
Novartis Investigative Site
City
Kashihara-city
State/Province
Nara
ZIP/Postal Code
634-8522
Country
Japan
Facility Name
Novartis Investigative Site
City
Okayama-city
State/Province
Okayama
ZIP/Postal Code
702-8055
Country
Japan
Facility Name
Novartis Investigative Site
City
Izumisano-city
State/Province
Osaka
ZIP/Postal Code
598-8577
Country
Japan
Facility Name
Novartis Investigative Site
City
Kita-ku
State/Province
Osaka
ZIP/Postal Code
530-0001
Country
Japan
Facility Name
Novartis Investigative Site
City
Osaka-city
State/Province
Osaka
ZIP/Postal Code
545-8586
Country
Japan
Facility Name
Novartis Investigative Site
City
Ureshino
State/Province
Saga
ZIP/Postal Code
843-0393
Country
Japan
Facility Name
Novartis Investigative Site
City
Hamada
State/Province
Shimane
ZIP/Postal Code
697-8511
Country
Japan
Facility Name
Novartis Investigative Site
City
Komatsushima-city
State/Province
Tokushima
ZIP/Postal Code
773-8502
Country
Japan
Facility Name
Novartis Investigative Site
City
Tokushima-city
State/Province
Tokushima
ZIP/Postal Code
770-8503
Country
Japan
Facility Name
Novartis Investigative Site
City
Adachi-ku
State/Province
Tokyo
ZIP/Postal Code
120-0006
Country
Japan
Facility Name
Novartis Investigative Site
City
Bunkyo-ku
State/Province
Tokyo
ZIP/Postal Code
113-8431
Country
Japan
Facility Name
Novartis Investigative Site
City
Bunkyo-ku
State/Province
Tokyo
ZIP/Postal Code
113-8519
Country
Japan
Facility Name
Novartis Investigative Site
City
Bunkyo-ku
State/Province
Tokyo
ZIP/Postal Code
113-8603
Country
Japan
Facility Name
Novartis Investigative Site
City
Bunkyo-ku
State/Province
Tokyo
ZIP/Postal Code
113-8655
Country
Japan
Facility Name
Novartis Investigative Site
City
Shinjuku-ku
State/Province
Tokyo
ZIP/Postal Code
162-8666
Country
Japan
Facility Name
Novartis Investigative Site
City
Hofu
State/Province
Yamaguchi
ZIP/Postal Code
747-8511
Country
Japan
Facility Name
Novartis Investigative Site
City
Shunan-city
State/Province
Yamaguchi
ZIP/Postal Code
745-8522
Country
Japan
Facility Name
Novartis Investigative Site
City
Ube
State/Province
Yamaguchi
ZIP/Postal Code
755-8505
Country
Japan
Facility Name
Novartis Investigative Site
City
Fukushima
ZIP/Postal Code
960-8251
Country
Japan
Facility Name
Novartis Investigative Site
City
Nagasaki
ZIP/Postal Code
850-8555
Country
Japan
Facility Name
Novartis Investigative Site
City
Saga
ZIP/Postal Code
849-8501
Country
Japan
Facility Name
Novartis Investigative Site
City
Toyama
ZIP/Postal Code
930-0194
Country
Japan
Facility Name
Novartis Investigative Site
City
Seongnam
State/Province
Gyeonggi
ZIP/Postal Code
13620
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Seoul
State/Province
Korea
ZIP/Postal Code
03080
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Seoul
State/Province
Korea
ZIP/Postal Code
03722
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Seoul
State/Province
Korea
ZIP/Postal Code
05505
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Seoul
State/Province
Korea
ZIP/Postal Code
06351
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Seoul
State/Province
Korea
ZIP/Postal Code
152-703
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Busan
ZIP/Postal Code
602-715
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Daejeon
ZIP/Postal Code
302-241
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Gwangju
ZIP/Postal Code
501-757
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Incheon
ZIP/Postal Code
405-760
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Seoul
ZIP/Postal Code
143-729
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Taegu
ZIP/Postal Code
700 - 721
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Daugavpils
ZIP/Postal Code
LV-5401
Country
Latvia
Facility Name
Novartis Investigative Site
City
Riga
ZIP/Postal Code
1012
Country
Latvia
Facility Name
Novartis Investigative Site
City
Riga
ZIP/Postal Code
LV-1012
Country
Latvia
Facility Name
Novartis Investigative Site
City
Riga
ZIP/Postal Code
LV-1038
Country
Latvia
Facility Name
Novartis Investigative Site
City
Kaunas
State/Province
LTU
ZIP/Postal Code
50009
Country
Lithuania
Facility Name
Novartis Investigative Site
City
Kaunas
ZIP/Postal Code
LT-47144
Country
Lithuania
Facility Name
Novartis Investigative Site
City
Klaipeda
ZIP/Postal Code
LT-92288
Country
Lithuania
Facility Name
Novartis Investigative Site
City
Vilnius
ZIP/Postal Code
08661
Country
Lithuania
Facility Name
Novartis Investigative Site
City
Guadalajara
State/Province
Jalisco
ZIP/Postal Code
44600
Country
Mexico
Facility Name
Novartis Investigative Site
City
Zapopan
State/Province
Jalisco
ZIP/Postal Code
45200
Country
Mexico
Facility Name
Novartis Investigative Site
City
Monterrey
State/Province
Nuevo León
ZIP/Postal Code
64060
Country
Mexico
Facility Name
Novartis Investigative Site
City
Monterrey
State/Province
Nuevo León
ZIP/Postal Code
64710
Country
Mexico
Facility Name
Novartis Investigative Site
City
Culiacan
State/Province
Sinaloa
ZIP/Postal Code
CP:83230
Country
Mexico
Facility Name
Novartis Investigative Site
City
Aguascalientes
ZIP/Postal Code
20230
Country
Mexico
Facility Name
Novartis Investigative Site
City
Querétaro
ZIP/Postal Code
76000
Country
Mexico
Facility Name
Novartis Investigative Site
City
San Luis Potosi
ZIP/Postal Code
78200
Country
Mexico
Facility Name
Novartis Investigative Site
City
Alkmaar
ZIP/Postal Code
1815 JD
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Amsterdam
ZIP/Postal Code
1023 NL
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Amsterdam
ZIP/Postal Code
1061 AE
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Amsterdam
ZIP/Postal Code
1091 HA
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Amsterdam
ZIP/Postal Code
1105 AZ
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Apeldoorn
ZIP/Postal Code
7334 DZ
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Deventer
ZIP/Postal Code
7416 SE
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Dirksland
ZIP/Postal Code
3247 BW
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Enschede
ZIP/Postal Code
7513 ER
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Groningen
ZIP/Postal Code
9713 GZ
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Haarlem
ZIP/Postal Code
2035 RC
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Heerlen
ZIP/Postal Code
6419 PC
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Leeuwarden
ZIP/Postal Code
8934 AD
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Leiderdorp
ZIP/Postal Code
NL-2353 GA
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Meppel
ZIP/Postal Code
7943 KA
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Rotterdam
ZIP/Postal Code
3045 PM
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Rotterdam
ZIP/Postal Code
3083 AN
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Venlo
ZIP/Postal Code
5912 BL
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Wildervank
ZIP/Postal Code
9648 BE
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Zutphen
ZIP/Postal Code
7207 AE
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Zwolle
ZIP/Postal Code
8011 JW
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Oslo
ZIP/Postal Code
0514
Country
Norway
Facility Name
Novartis Investigative Site
City
Trondheim
ZIP/Postal Code
7006
Country
Norway
Facility Name
Novartis Investigative Site
City
Tønsberg
ZIP/Postal Code
3116
Country
Norway
Facility Name
Novartis Investigative Site
City
Trujillo
State/Province
La Libertad
Country
Peru
Facility Name
Novartis Investigative Site
City
Chiclayo
State/Province
Lambayeque
Country
Peru
Facility Name
Novartis Investigative Site
City
Bellavista
State/Province
Lima
ZIP/Postal Code
Callao 02
Country
Peru
Facility Name
Novartis Investigative Site
City
Cercado de Lima
State/Province
Lima
ZIP/Postal Code
01
Country
Peru
Facility Name
Novartis Investigative Site
City
Jesus Maria
State/Province
Lima
ZIP/Postal Code
11
Country
Peru
Facility Name
Novartis Investigative Site
City
Miraflores
State/Province
Lima
ZIP/Postal Code
18
Country
Peru
Facility Name
Novartis Investigative Site
City
San Borja
State/Province
Lima
ZIP/Postal Code
41
Country
Peru
Facility Name
Novartis Investigative Site
City
San Isidro
State/Province
Lima
ZIP/Postal Code
27
Country
Peru
Facility Name
Novartis Investigative Site
City
San Juan de Miraflores
State/Province
Lima
ZIP/Postal Code
29
Country
Peru
Facility Name
Novartis Investigative Site
City
Lima
ZIP/Postal Code
Lima 39
Country
Peru
Facility Name
Novartis Investigative Site
City
Bytom
ZIP/Postal Code
41-902
Country
Poland
Facility Name
Novartis Investigative Site
City
Chorzow
ZIP/Postal Code
41-506
Country
Poland
Facility Name
Novartis Investigative Site
City
Gdansk
ZIP/Postal Code
80-180
Country
Poland
Facility Name
Novartis Investigative Site
City
Gdynia
ZIP/Postal Code
81-423
Country
Poland
Facility Name
Novartis Investigative Site
City
Gdynia
ZIP/Postal Code
81-519
Country
Poland
Facility Name
Novartis Investigative Site
City
Gliwice
ZIP/Postal Code
44-100
Country
Poland
Facility Name
Novartis Investigative Site
City
Grodzisk Mazowiecki
ZIP/Postal Code
05-825
Country
Poland
Facility Name
Novartis Investigative Site
City
Katowice
ZIP/Postal Code
40-040
Country
Poland
Facility Name
Novartis Investigative Site
City
Katowice
ZIP/Postal Code
40-084
Country
Poland
Facility Name
Novartis Investigative Site
City
Klodzko
ZIP/Postal Code
57-300
Country
Poland
Facility Name
Novartis Investigative Site
City
Krakow
ZIP/Postal Code
30-053
Country
Poland
Facility Name
Novartis Investigative Site
City
Kraków
ZIP/Postal Code
31-501
Country
Poland
Facility Name
Novartis Investigative Site
City
Lomza
ZIP/Postal Code
18-104
Country
Poland
Facility Name
Novartis Investigative Site
City
Olawa
ZIP/Postal Code
55-200
Country
Poland
Facility Name
Novartis Investigative Site
City
Opole
ZIP/Postal Code
45-706
Country
Poland
Facility Name
Novartis Investigative Site
City
Ostrow Wielkopolski
ZIP/Postal Code
63-400
Country
Poland
Facility Name
Novartis Investigative Site
City
Ostrowiec Swietokrzyski
ZIP/Postal Code
27-400
Country
Poland
Facility Name
Novartis Investigative Site
City
Piotrkow Trybunalski
ZIP/Postal Code
97-300
Country
Poland
Facility Name
Novartis Investigative Site
City
Plock
ZIP/Postal Code
09-402
Country
Poland
Facility Name
Novartis Investigative Site
City
Poznan
ZIP/Postal Code
61-485
Country
Poland
Facility Name
Novartis Investigative Site
City
Sandomierz
ZIP/Postal Code
27-600
Country
Poland
Facility Name
Novartis Investigative Site
City
Tarnow
ZIP/Postal Code
33-100
Country
Poland
Facility Name
Novartis Investigative Site
City
Torun
ZIP/Postal Code
87-100
Country
Poland
Facility Name
Novartis Investigative Site
City
Warszawa
ZIP/Postal Code
03-242
Country
Poland
Facility Name
Novartis Investigative Site
City
Warszawa
ZIP/Postal Code
04-628
Country
Poland
Facility Name
Novartis Investigative Site
City
Wroclaw
ZIP/Postal Code
50-349
Country
Poland
Facility Name
Novartis Investigative Site
City
Wroclaw
ZIP/Postal Code
50-420
Country
Poland
Facility Name
Novartis Investigative Site
City
Wroclaw
ZIP/Postal Code
50-981
Country
Poland
Facility Name
Novartis Investigative Site
City
Wroclaw
ZIP/Postal Code
52-612
Country
Poland
Facility Name
Novartis Investigative Site
City
Zabrze
ZIP/Postal Code
41-800
Country
Poland
Facility Name
Novartis Investigative Site
City
Amadora
ZIP/Postal Code
2720-276
Country
Portugal
Facility Name
Novartis Investigative Site
City
Aveiro
ZIP/Postal Code
3814-501
Country
Portugal
Facility Name
Novartis Investigative Site
City
Carnaxide
ZIP/Postal Code
2799-523
Country
Portugal
Facility Name
Novartis Investigative Site
City
Coimbra
ZIP/Postal Code
3000-075
Country
Portugal
Facility Name
Novartis Investigative Site
City
Faro
ZIP/Postal Code
8000-386
Country
Portugal
Facility Name
Novartis Investigative Site
City
Lisboa
ZIP/Postal Code
1495-005
Country
Portugal
Facility Name
Novartis Investigative Site
City
Lisboa
ZIP/Postal Code
1600-190
Country
Portugal
Facility Name
Novartis Investigative Site
City
Lisboa
ZIP/Postal Code
1769-001
Country
Portugal
Facility Name
Novartis Investigative Site
City
Penafiel
ZIP/Postal Code
4564-007
Country
Portugal
Facility Name
Novartis Investigative Site
City
Porto
ZIP/Postal Code
4200-319
Country
Portugal
Facility Name
Novartis Investigative Site
City
Humacao
ZIP/Postal Code
00791
Country
Puerto Rico
Facility Name
Novartis Investigative Site
City
Ponce
ZIP/Postal Code
00717
Country
Puerto Rico
Facility Name
Novartis Investigative Site
City
San Juan
ZIP/Postal Code
00936-6528
Country
Puerto Rico
Facility Name
Novartis Investigative Site
City
Bucharest
State/Province
District 1
ZIP/Postal Code
012051
Country
Romania
Facility Name
Novartis Investigative Site
City
Bucharest
State/Province
District 1
ZIP/Postal Code
012064
Country
Romania
Facility Name
Novartis Investigative Site
City
Bucharest
State/Province
District 2
ZIP/Postal Code
021705
Country
Romania
Facility Name
Novartis Investigative Site
City
Iasi
State/Province
Jud Iasi
ZIP/Postal Code
700005
Country
Romania
Facility Name
Novartis Investigative Site
City
Targu Mures
State/Province
jud Mures
ZIP/Postal Code
540043
Country
Romania
Facility Name
Novartis Investigative Site
City
Iasi
State/Province
Jud. Iasi
ZIP/Postal Code
700506
Country
Romania
Facility Name
Novartis Investigative Site
City
Targu Mures
State/Province
Mures
ZIP/Postal Code
540136
Country
Romania
Facility Name
Novartis Investigative Site
City
Baia Mare
ZIP/Postal Code
430123
Country
Romania
Facility Name
Novartis Investigative Site
City
Brasov
ZIP/Postal Code
500281
Country
Romania
Facility Name
Novartis Investigative Site
City
Brasov
ZIP/Postal Code
500427
Country
Romania
Facility Name
Novartis Investigative Site
City
Cluj Napoca
ZIP/Postal Code
400006
Country
Romania
Facility Name
Novartis Investigative Site
City
Cluj-Napoca
ZIP/Postal Code
400347
Country
Romania
Facility Name
Novartis Investigative Site
City
Iasi
ZIP/Postal Code
700547
Country
Romania
Facility Name
Novartis Investigative Site
City
Oradea
ZIP/Postal Code
410169
Country
Romania
Facility Name
Novartis Investigative Site
City
Pitesti
ZIP/Postal Code
110114
Country
Romania
Facility Name
Novartis Investigative Site
City
Targu Mures
ZIP/Postal Code
540096
Country
Romania
Facility Name
Novartis Investigative Site
City
Timisoara
ZIP/Postal Code
300310
Country
Romania
Facility Name
Novartis Investigative Site
City
Timisoara
ZIP/Postal Code
300736
Country
Romania
Facility Name
Novartis Investigative Site
City
Barnaul
ZIP/Postal Code
656055
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Chelyabinsk
ZIP/Postal Code
454000
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Chelyabinsk
ZIP/Postal Code
454021
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Chelyabinsk
ZIP/Postal Code
454047
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Chelyabinsk
ZIP/Postal Code
454048
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Ekaterinburg
ZIP/Postal Code
620028
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Ekaterinburg
ZIP/Postal Code
620137
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Izhevsk
ZIP/Postal Code
426009
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Kirov
ZIP/Postal Code
610014
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Krasnodar
ZIP/Postal Code
350063
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Kursk
ZIP/Postal Code
305035
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Lubertsi
ZIP/Postal Code
140006
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
105229
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
111020
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
111539
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
115432
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
117292
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
119992
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
121359
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
127473
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
129301
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Nizhny Novgorod
ZIP/Postal Code
603018
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Novosibirsk
ZIP/Postal Code
630047
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Novosibirsk
ZIP/Postal Code
630075
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Novosibirsk
ZIP/Postal Code
630089
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Omsk
ZIP/Postal Code
644018
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Perm
ZIP/Postal Code
614097
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Pushkin,St-Petersburg
ZIP/Postal Code
196601
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Ryazan
ZIP/Postal Code
390026
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
S.-Petersburg
ZIP/Postal Code
196247
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Saint Petersburg
ZIP/Postal Code
197022
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Saint-Petersburg
ZIP/Postal Code
194044
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Saint-Petersburg
ZIP/Postal Code
197341
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Saratov
ZIP/Postal Code
410012
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Saratov
ZIP/Postal Code
410028
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
St-Petersburg
ZIP/Postal Code
191119
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
St. Petersburg
ZIP/Postal Code
198013
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Tyumen
ZIP/Postal Code
625026
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Volgograd
ZIP/Postal Code
400001
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Volgograd
ZIP/Postal Code
400008
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Voronezh
ZIP/Postal Code
394065
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Yaroslavl
ZIP/Postal Code
150000
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Yaroslavl
ZIP/Postal Code
150030
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Yaroslavl
ZIP/Postal Code
150062
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Bratislava
State/Province
Slovak Republic
ZIP/Postal Code
812 72
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Bratislava
State/Province
Slovak Republic
ZIP/Postal Code
826 06
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Komarno
State/Province
Slovak Republic
ZIP/Postal Code
94575
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Kosice
State/Province
Slovak Republic
ZIP/Postal Code
040 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Kosice
State/Province
Slovak republic
ZIP/Postal Code
04166
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Levice
State/Province
Slovak Republic
ZIP/Postal Code
93401
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Nitra
State/Province
Slovak Republic
ZIP/Postal Code
949 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Povazska Bystrica
State/Province
Slovak republic
ZIP/Postal Code
01701
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Presov
State/Province
Slovak republic
ZIP/Postal Code
08101
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Stropkov
State/Province
Slovak republic
ZIP/Postal Code
09101
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Zilina
State/Province
Slovak Republic
ZIP/Postal Code
010 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Zilina
State/Province
Slovak Republic
ZIP/Postal Code
08001
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Bardejov
ZIP/Postal Code
085 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Bratislava
ZIP/Postal Code
81369
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Kosice
ZIP/Postal Code
040 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Kosice
ZIP/Postal Code
04001
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Lucenec
ZIP/Postal Code
98439
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Piestany
ZIP/Postal Code
921 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Presov
ZIP/Postal Code
080 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Trebisov
ZIP/Postal Code
075 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Trencin
ZIP/Postal Code
911 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Zilina
ZIP/Postal Code
012 07
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Soweto
State/Province
Gauteng
ZIP/Postal Code
2013
Country
South Africa
Facility Name
Novartis Investigative Site
City
Benoni
Country
South Africa
Facility Name
Novartis Investigative Site
City
Boksburg
Country
South Africa
Facility Name
Novartis Investigative Site
City
Centurion
ZIP/Postal Code
4001
Country
South Africa
Facility Name
Novartis Investigative Site
City
Johannesburg
ZIP/Postal Code
2157
Country
South Africa
Facility Name
Novartis Investigative Site
City
Western Cape
ZIP/Postal Code
7130
Country
South Africa
Facility Name
Novartis Investigative Site
City
Worcester
ZIP/Postal Code
6850
Country
South Africa
Facility Name
Novartis Investigative Site
City
Sanlucar de Barrameda
State/Province
Andalucia
ZIP/Postal Code
11540
Country
Spain
Facility Name
Novartis Investigative Site
City
Sevilla
State/Province
Andalucia
ZIP/Postal Code
41009
Country
Spain
Facility Name
Novartis Investigative Site
City
Utrera
State/Province
Andalucia
ZIP/Postal Code
41710
Country
Spain
Facility Name
Novartis Investigative Site
City
Oviedo
State/Province
Asturias
ZIP/Postal Code
33011
Country
Spain
Facility Name
Novartis Investigative Site
City
Hospitalet de Llobregat
State/Province
Barcelona
ZIP/Postal Code
08907
Country
Spain
Facility Name
Novartis Investigative Site
City
Villamartin
State/Province
Cadiz
ZIP/Postal Code
11650
Country
Spain
Facility Name
Novartis Investigative Site
City
Badalona
State/Province
Catalunya
ZIP/Postal Code
08916
Country
Spain
Facility Name
Novartis Investigative Site
City
Barcelona
State/Province
Catalunya
ZIP/Postal Code
08035
Country
Spain
Facility Name
Novartis Investigative Site
City
Barcelona
State/Province
Catalunya
ZIP/Postal Code
08036
Country
Spain
Facility Name
Novartis Investigative Site
City
Tarragona
State/Province
Catalunya
ZIP/Postal Code
43005
Country
Spain
Facility Name
Novartis Investigative Site
City
Tortosa
State/Province
Cataluña
ZIP/Postal Code
43500
Country
Spain
Facility Name
Novartis Investigative Site
City
Alicante
State/Province
Comunidad Valenciana
ZIP/Postal Code
03004
Country
Spain
Facility Name
Novartis Investigative Site
City
Valencia
State/Province
Comunidad Valenciana
ZIP/Postal Code
46014
Country
Spain
Facility Name
Novartis Investigative Site
City
Santiago de Compostela
State/Province
Galicia
ZIP/Postal Code
15706
Country
Spain
Facility Name
Novartis Investigative Site
City
Majadahonda
State/Province
Madrid
ZIP/Postal Code
28222
Country
Spain
Facility Name
Novartis Investigative Site
City
Valdemoro
State/Province
Madrid
ZIP/Postal Code
28342
Country
Spain
Facility Name
Novartis Investigative Site
City
Barcelona
ZIP/Postal Code
08041
Country
Spain
Facility Name
Novartis Investigative Site
City
Madrid
ZIP/Postal Code
28007
Country
Spain
Facility Name
Novartis Investigative Site
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Novartis Investigative Site
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Facility Name
Novartis Investigative Site
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Facility Name
Novartis Investigative Site
City
Madrid
ZIP/Postal Code
28049
Country
Spain
Facility Name
Novartis Investigative Site
City
Falun
ZIP/Postal Code
791 82
Country
Sweden
Facility Name
Novartis Investigative Site
City
Göteborg
ZIP/Postal Code
416 85
Country
Sweden
Facility Name
Novartis Investigative Site
City
Karlstad
ZIP/Postal Code
681 85
Country
Sweden
Facility Name
Novartis Investigative Site
City
Linkoping
ZIP/Postal Code
581 85
Country
Sweden
Facility Name
Novartis Investigative Site
City
Lund
ZIP/Postal Code
SE-222 21
Country
Sweden
Facility Name
Novartis Investigative Site
City
Malmo
ZIP/Postal Code
SE 211 36
Country
Sweden
Facility Name
Novartis Investigative Site
City
Malmö
ZIP/Postal Code
205 02
Country
Sweden
Facility Name
Novartis Investigative Site
City
Malmö
ZIP/Postal Code
214 22
Country
Sweden
Facility Name
Novartis Investigative Site
City
Mölndal
ZIP/Postal Code
431 80
Country
Sweden
Facility Name
Novartis Investigative Site
City
Nässjö
ZIP/Postal Code
SE 571 31
Country
Sweden
Facility Name
Novartis Investigative Site
City
Skelleftea
ZIP/Postal Code
931 86
Country
Sweden
Facility Name
Novartis Investigative Site
City
Stockholm
ZIP/Postal Code
111 57
Country
Sweden
Facility Name
Novartis Investigative Site
City
Stockholm
ZIP/Postal Code
112 81
Country
Sweden
Facility Name
Novartis Investigative Site
City
Stockholm
ZIP/Postal Code
17176
Country
Sweden
Facility Name
Novartis Investigative Site
City
Stockholm
ZIP/Postal Code
SE-111 35
Country
Sweden
Facility Name
Novartis Investigative Site
City
Sundsvall
ZIP/Postal Code
851 86
Country
Sweden
Facility Name
Novartis Investigative Site
City
Sundsvall
ZIP/Postal Code
852 31
Country
Sweden
Facility Name
Novartis Investigative Site
City
Umeå
ZIP/Postal Code
901 85
Country
Sweden
Facility Name
Novartis Investigative Site
City
Uppsala
ZIP/Postal Code
SE-751 85
Country
Sweden
Facility Name
Novartis Investigative Site
City
Västerås
ZIP/Postal Code
s-721 89
Country
Sweden
Facility Name
Novartis Investigative Site
City
Örebro
ZIP/Postal Code
701 85
Country
Sweden
Facility Name
Novartis Investigative Site
City
Basel
ZIP/Postal Code
4031
Country
Switzerland
Facility Name
Novartis Investigative Site
City
Bellinzona
ZIP/Postal Code
6500
Country
Switzerland
Facility Name
Novartis Investigative Site
City
Bern
ZIP/Postal Code
3010
Country
Switzerland
Facility Name
Novartis Investigative Site
City
Biel
ZIP/Postal Code
2500
Country
Switzerland
Facility Name
Novartis Investigative Site
City
Bruderholz
ZIP/Postal Code
4101
Country
Switzerland
Facility Name
Novartis Investigative Site
City
Lugano
ZIP/Postal Code
6903
Country
Switzerland
Facility Name
Novartis Investigative Site
City
Olten
ZIP/Postal Code
4600
Country
Switzerland
Facility Name
Novartis Investigative Site
City
Winterthur
ZIP/Postal Code
8401
Country
Switzerland
Facility Name
Novartis Investigative Site
City
Zuerich
ZIP/Postal Code
8091
Country
Switzerland
Facility Name
Novartis Investigative Site
City
Yongkang
State/Province
Tainan
ZIP/Postal Code
71004
Country
Taiwan
Facility Name
Novartis Investigative Site
City
Tainan 704
State/Province
Taiwan ROC
ZIP/Postal Code
70403
Country
Taiwan
Facility Name
Novartis Investigative Site
City
Kaohsiung
ZIP/Postal Code
807
Country
Taiwan
Facility Name
Novartis Investigative Site
City
Lin-Kou
ZIP/Postal Code
33305
Country
Taiwan
Facility Name
Novartis Investigative Site
City
Niaosong Township
ZIP/Postal Code
83301
Country
Taiwan
Facility Name
Novartis Investigative Site
City
Taichung
ZIP/Postal Code
40447
Country
Taiwan
Facility Name
Novartis Investigative Site
City
Taipei
ZIP/Postal Code
10002
Country
Taiwan
Facility Name
Novartis Investigative Site
City
Taipei
ZIP/Postal Code
104
Country
Taiwan
Facility Name
Novartis Investigative Site
City
Bangkok
ZIP/Postal Code
10330
Country
Thailand
Facility Name
Novartis Investigative Site
City
Bangkok
ZIP/Postal Code
10400
Country
Thailand
Facility Name
Novartis Investigative Site
City
Bangkok
ZIP/Postal Code
10700
Country
Thailand
Facility Name
Novartis Investigative Site
City
Chiang Mai
ZIP/Postal Code
50200
Country
Thailand
Facility Name
Novartis Investigative Site
City
Ankara
ZIP/Postal Code
06100
Country
Turkey
Facility Name
Novartis Investigative Site
City
Aydin
ZIP/Postal Code
09100
Country
Turkey
Facility Name
Novartis Investigative Site
City
Balcova / Izmir
ZIP/Postal Code
35340
Country
Turkey
Facility Name
Novartis Investigative Site
City
Etlik / Ankara
ZIP/Postal Code
06018
Country
Turkey
Facility Name
Novartis Investigative Site
City
Fatih / Istanbul
ZIP/Postal Code
34098
Country
Turkey
Facility Name
Novartis Investigative Site
City
Istanbul
ZIP/Postal Code
34304
Country
Turkey
Facility Name
Novartis Investigative Site
City
Izmir
ZIP/Postal Code
35040
Country
Turkey
Facility Name
Novartis Investigative Site
City
Kinikli / Denizli
ZIP/Postal Code
20070
Country
Turkey
Facility Name
Novartis Investigative Site
City
Kocaeli
ZIP/Postal Code
41380
Country
Turkey
Facility Name
Novartis Investigative Site
City
Sivas
ZIP/Postal Code
58140
Country
Turkey
Facility Name
Novartis Investigative Site
City
Leicester
State/Province
Leicestershire
ZIP/Postal Code
LE3 9QP
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Dafen
State/Province
Llanelli
ZIP/Postal Code
SA14 8QF
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Addlestone
State/Province
Surrey
ZIP/Postal Code
KT15 2BH
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Chichester
State/Province
West Sussex
ZIP/Postal Code
PO19 6SE
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Worthing
State/Province
West Sussex
ZIP/Postal Code
BN11 2DH
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Cardiff
ZIP/Postal Code
CF5 4AD
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Chesterfield
ZIP/Postal Code
S44 5BL
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Colchester
ZIP/Postal Code
CO4 5JL
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
East Yorkshire
ZIP/Postal Code
HU16 5JQ
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Glasgow
ZIP/Postal Code
G51 4TF
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Liverpool
ZIP/Postal Code
L14 3PE
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
London
ZIP/Postal Code
SE1 7EH
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
London
ZIP/Postal Code
SW17 0RE
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Manchester
ZIP/Postal Code
M23 9LT
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Southampton
ZIP/Postal Code
SO16 6YD
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Swindon
ZIP/Postal Code
SN3 6BB
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Caracas
State/Province
Distrito Capital
ZIP/Postal Code
1010
Country
Venezuela
Facility Name
Novartis Investigative Site
City
Caracas
State/Province
Distrito Capital
ZIP/Postal Code
1040
Country
Venezuela
Facility Name
Novartis Investigative Site
City
Caracas
State/Province
Distrito Capital
ZIP/Postal Code
1060
Country
Venezuela
Facility Name
Novartis Investigative Site
City
Valencia
State/Province
Edo. Carabobo
ZIP/Postal Code
2001
Country
Venezuela
Facility Name
Novartis Investigative Site
City
Barcelona
State/Province
Estado Anzoátegui
ZIP/Postal Code
6001
Country
Venezuela
Facility Name
Novartis Investigative Site
City
Puerto Ordaz
State/Province
Estado Bolívar
ZIP/Postal Code
8050
Country
Venezuela
Facility Name
Novartis Investigative Site
City
Caracas
State/Province
Estado Miranda
ZIP/Postal Code
1061
Country
Venezuela
Facility Name
Novartis Investigative Site
City
Cumana
State/Province
Estado Sucre
ZIP/Postal Code
6101
Country
Venezuela
Facility Name
Novartis Investigative Site
City
Maracaibo
State/Province
Estado Zulia
ZIP/Postal Code
4011
Country
Venezuela

12. IPD Sharing Statement

Citations:
PubMed Identifier
34101002
Citation
Shen L, Claggett BL, Jhund PS, Abraham WT, Desai AS, Dickstein K, Gong J, Kober LV, Lefkowitz MP, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, McMurray JJV. Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. Clin Res Cardiol. 2021 Aug;110(8):1334-1349. doi: 10.1007/s00392-021-01888-x. Epub 2021 Jun 8.
Results Reference
derived
PubMed Identifier
33089502
Citation
Wang GM, Li LJ, Tang WL, Wright JM. Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2020 Oct 22;10(10):CD012569. doi: 10.1002/14651858.CD012569.pub2.
Results Reference
derived
PubMed Identifier
32720404
Citation
Kristensen SL, Castagno D, Shen L, Jhund PS, Docherty KF, Rorth R, Abraham WT, Desai AS, Dickstein K, Rouleau JL, Zile MR, Swedberg K, Packer M, Solomon SD, Kober L, McMurray JJV; PARADIGM-HF and ATMOSPHERE Committees and Investigators.. Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. Eur J Heart Fail. 2020 Dec;22(12):2370-2379. doi: 10.1002/ejhf.1972. Epub 2020 Sep 14.
Results Reference
derived
PubMed Identifier
31849164
Citation
Docherty KF, Shen L, Castagno D, Petrie MC, Abraham WT, Bohm M, Desai AS, Dickstein K, Kober LV, Packer M, Rouleau JL, Solomon SD, Swedberg K, Vazir A, Zile MR, Jhund PS, McMurray JJV. Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. Eur J Heart Fail. 2020 Mar;22(3):528-538. doi: 10.1002/ejhf.1682. Epub 2019 Dec 17.
Results Reference
derived
PubMed Identifier
31813280
Citation
Dewan P, Rorth R, Raparelli V, Campbell RT, Shen L, Jhund PS, Petrie MC, Anand IS, Carson PE, Desai AS, Granger CB, Kober L, Komajda M, McKelvie RS, O'Meara E, Pfeffer MA, Pitt B, Solomon SD, Swedberg K, Zile MR, McMurray JJV. Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2019 Dec;12(12):e006539. doi: 10.1161/CIRCHEARTFAILURE.119.006539. Epub 2019 Dec 9. Erratum In: Circ Heart Fail. 2020 Jan;13(1):e000036.
Results Reference
derived
PubMed Identifier
29141857
Citation
Shen L, Ramires F, Martinez F, Bodanese LC, Echeverria LE, Gomez EA, Abraham WT, Dickstein K, Kober L, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Jhund PS, Gimpelewicz CR, McMurray JJV; PARADIGM-HF and ATMOSPHERE Investigators and Committees. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. Circ Heart Fail. 2017 Nov;10(11):e004361. doi: 10.1161/CIRCHEARTFAILURE.117.004361.
Results Reference
derived
PubMed Identifier
29018174
Citation
Kristensen SL, Jhund PS, Mogensen UM, Rorth R, Abraham WT, Desai A, Dickstein K, Rouleau JL, Zile MR, Swedberg K, Packer M, Solomon SD, Kober L, McMurray JJV; PARADIGM-HF and ATMOSPHERE Committees and Investigators. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Circ Heart Fail. 2017 Oct;10(10):e004409. doi: 10.1161/CIRCHEARTFAILURE.117.004409.
Results Reference
derived
PubMed Identifier
28948656
Citation
Kristensen SL, Mogensen UM, Tarnesby G, Gimpelewicz CR, Ali MA, Shao Q, Chiang Y, Jhund PS, Abraham WT, Dickstein K, McMurray JJV, Kober L. Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial. Eur J Heart Fail. 2018 Jan;20(1):136-147. doi: 10.1002/ejhf.896. Epub 2017 Sep 25.
Results Reference
derived
PubMed Identifier
27043774
Citation
McMurray JJ, Krum H, Abraham WT, Dickstein K, Kober LV, Desai AS, Solomon SD, Greenlaw N, Ali MA, Chiang Y, Shao Q, Tarnesby G, Massie BM; ATMOSPHERE Committees Investigators. Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. N Engl J Med. 2016 Apr 21;374(16):1521-32. doi: 10.1056/NEJMoa1514859. Epub 2016 Apr 4.
Results Reference
derived

Learn more about this trial

Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure

We'll reach out to this number within 24 hrs